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ABSTRACT

THE ROLE OF KLF1 IN REGULATING γ-GLOBIN GENE REPRESSORS
By Anna P. Kovilakath, M.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University.
Virginia Commonwealth University, 2017.
Major Director: Joyce A. Lloyd, Professor, Vice Chair of Education
Department of Human and Molecular Genetics, School of Medicine
Sickle cell disease and β-thalassemia affect millions of people worldwide. γ-globin is the
fetal counterpart to the adult β-globin. Research has shown that affected patients with higher than
normal γ-globin show less severe symptoms. Therefore, reversing or preventing the hemoglobin
switch from γ- to β- globin is a promising avenue of research for treating these diseases.
KLF1 is an erythroid transcription factor involved in hemoglobin switching. Herein, we
show that KLF1 directly regulates the γ-globin repressor gene LRF in both the mouse and human
systems. KLF1 may also directly activate γ-globin expression by binding the promoter. In human
HUDEP-2 cells, an increase in γ-globin expression is seen upon modest knockdown (~50%) of
KLF1, whereas normal amounts of KLF1 are observed upon robust knockdown (>75%) of
KLF1. The data suggest that KLF1 plays both a positive and negative role in -globin expression.

Chapter 1: Introduction

The production of all blood cells and platelets in the body is termed hematopoiesis. It is one
of the first processes established in developing mammalian embryos because it involves the
synthesis of red and white blood cells (Figure 1.1). In both mice and humans, hemangioblast
precursors are synthesized during gastrulation, prior to the formation of hematopoietic
progenitors, including primitive erythroid progenitors (Sabin, 1920; Choi et al., 1998; Zambidis
et al., 2005; Kennedy et al., 2007). After this, the process of hematopoiesis occurs in three waves
throughout mammalian development in various anatomical sites of the body. The first occurs in
the yolk sac to produce megakaryocytes, macrophages and primitive erythroid cells and is
primitive. The second wave also occurs in the yolk sac to produce megakaryocytes, several
myeloid lineages and definitive erythroid cells (Tavian M, 2005; Tober Koniski, 2007; James
Palis, 1999), but is definitive. The third wave is also definitive and involves hematopoietic stem
cells (HSCs) which are produced within the major arteries of the embryo, yolk sac, and placenta
(Lee LK, 2010). These HSCs expand within the fetal liver during fetal development and then
move to the bone marrow after birth (Kumaravelu P, 2002).
1.1 Erythropoiesis
The synthesis of erythrocytes (red blood cells) from earlier hematopoietic and progenitor
cells is termed erythropoiesis. Erythroid cells are the first cells to be specified and developed in
the post-implantation mammalian embryo. Primitive and definitive erythropoiesis are the two
types of erythropoiesis in mammals (Figure 1.2) due to the presence of two morphologically and
developmentally distinct cell populations in the bloodstream of vertebrates (Gulliver, 1875;
Baron and Fraser, 2005; McGrath and Palis, 2005; Fraser et al., 2007; Palis J, 2008).
1

Figure 1.1: Progenitor Cell Lineages of Pluripotent Hematopoietic Stem Cells
Pluripotent hematopoietic stem cells (HSCs) have the ability to differentiate into the progenitors of all
types of mature blood cells. CFU-E/CFU-M/CFU-GM = Colony forming UnitErythroid/Megakaryocyte /Granulocyte-Monocyte. This study focuses on the lineage from the CFU-E
lineage cells and all samples collected in both mice and human systems are at varying erythroblastic
stages. Figure adapted from http://nhealthcare.blogspot.com/ 2013/04/red-blood-cell-formationerythropoiesis.html, accession date: June 19th, 2017
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1.1.1 Primitive Erythropoiesis
Primitive erythropoiesis, also termed embryonic erythropoiesis, produces erythroid
progenitor colony forming cells (EryP-CFCs) in the blood islands of the yolk sac of the embryo
(Wong, 1986; Palis J, 1999; Isern J, 2011) starting from embryonic day 7.5 (E7.5) in mice and
two weeks in humans after conception (McGrath and Palis, 2005; Qiu et al., 2008). Primitive
erythropoiesis results in the formation of embryonic hemoglobin in vertebrates
(Papayannopoulou T et al., 1980; Karlsson and Nienhuis, 1985), further discussion on types of
hemoglobin is in section 1.2.1. Blood circulation starts upon initiation of the first heartbeat
around E8.25 in mice and in the 8th week of development in humans (Ji et al., 2003; Palis, 2008).
The EryP-CFCs differentiate from the mesoderm just after gastrulation and are capable of
forming colonies of large, mature erythrocytes which become enucleate. Their differentiated
progeny remain in circulation even after birth but are outnumbered by the definitive erythroid
cells formed in the growing fetal liver of the fetus (Palis J, 1999; Kingsley PD, 2004).
The maturation of EryPs during development remains poorly understood, but they give rise
to primitive erythroid precursors which gradually mature to become smaller, accumulate
hemoglobin and undergo nuclear pyknosis and decreased RNA content. Only recently was it
discovered that primitive erythroblasts enucleate as a process of maturation into primitive
erythrocytes between E12.5 – E16.5 in mice and 18-20 days in humans (Kingsley 2004).
Primitive erythrocytes are still present in the bloodstream several days after birth and have an
unknown lifespan (Kingsley, 2004; Fraser, 2007).
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1.1.2 Definitive Erythropoiesis
Definitive erythroid cells originate from the pool of HSCs in the fetal liver in utero and are
detected at E11.5 and six-weeks in mouse and human embryos respectively (Kingsley et al.,
2006; Qiu et al., 2008). After birth definitive erythroid cells emerge from the HSCs present in
bone marrow throughout postnatal life (Orkin SH, 2008; Dzierzak, 2008). Therefore, definitive
erythropoiesis results in the formation of both fetal and adult hemoglobin in humans and solely
adult hemoglobin in other vertebrates including mice (Maniatis et al. 1980; Karlsson and
Nienhuis 1985), further discussion on types of hemoglobin is in section 1.2.1. The earliest
definitive progenitor cells termed burst-forming unit erythroid (BFU-E) are small with no
particular histology characteristic and express the cell surface marker CD34 which all early
hematopoietic progenitors express. They could be considered the counterpart to the EryP-CFCs
seen in primitive erythropoiesis. The BFU-Es give rise to the morphologically larger colonyforming unit erythroid (CFU-E) progenitor cells. Both of these definitive erythroid progenitor
cells are lineage-committed and are capable of forming colonies of mature erythrocytes (Frame,
J.M., 2013).
CFU-E give rise to the first immature precursor cells proerythroblasts which produce
hemoglobin. They mature in the sequential order from proerythroblasts (ProE), basophiliic
erythroblasts (BasoE), polychromatophilic erythroblasts (PolyE), and finally to orthochromatic
erythroblasts (OrthoE). The orthochromatic erythroblasts are smaller, have higher accumulation
of hemoglobin, irreversible chromatin condensation and decrease in RNA content similar to the
maturation process in primitive erythropoiesis. Maturation of erythroblasts occurs in the fetal
liver in utero and bone marrow after birth within erythroblasts attached to a central macrophage
termed erythroblastic islands (Chasis and Mohandas, 2008).
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After nuclear pyknosis, the mature erythroid precursors completely expel their condensed
chromatin to become enucleate and form immature erythrocytes, reticulocytes. The final stage of
definitive erythropoiesis contains circulating reticulocytes and mature erythrocytes.
Reticulocytes are released and circulate in the blood to balance the amount of erythrocytes
present in the bloodstream due to removal of senescent erythrocytes after 120 days by splenic
macrophages into the spleen (Bennett and Kay, 1981).
To determine whether the primitive or definitive cells are maturing erythroid cells
(proerythroblasts), two cell surface marker antigens are used via flow cytometry (Zhang et al.
2003). The two markers used are the transferrin receptor (CD71) and glycophorin A (CD235A)
in humans and the transferrin receptor (CD71) and Ter119 in mice.

1.1.3 Regulation of Erythropoiesis
The activity of erythroid-specific and non-erythroid specific transcription factors and
cytokines in the overall process of erythropoiesis has been elucidated in studies of their
activation in leukemic translocations and in the effect seen in embryonic stem cells upon their
disruption (Shivdasani RA, 1996). This is of clinical importance because β-hemoglobinopathies
like sickle cell disease and β-thalassemias, (discussed further in Section 1.3.1), affect many
people. But patients with one or more of these diseases show ameliorated symptoms if they have
naturally occurring mutations that cause HPFH (discussed further in Section 1.3.2). This is why a
lot of past and ongoing research has specifically worked on identifying and targeting γ-globin
gene repressors to reverse the hemoglobin switch or reactivate fetal globin gene expression
(Sankaran VG et al., 2013; Philipsen, 2013).
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Tal-1/SCL is a basic helix-loop-helix transcription factor expressed in both primitive and
definitive erythropoietic cells, mast cells, megakaryocytes, endothelial cells and T-cell acute
lymphoblastic leukemia (Begley CG et al., 1989; Finger LR et al., 1989; Mouthon MA et al.,
1993). Its primary role is with erythroid and megakaryocyte lineages differentiation (Mikkola
HK, 2003). Knockout of the TAL-1 gene in in vitro and in vivo leads to in utero death from
absence of myeloid colony and blood formation (Shivdasani RA, 1995; Robb L, 1995).
LIM-only domain nuclear protein rhombotin 2 (Rbtn2/LMO2) is another transcription factor
involved in erythropoiesis (Boehm T, 1991; Warren AJ, 1994). It has been shown that LMO2
complexes with Tal-1/SCL for primitive erythropoiesis to occur (Valge-Archer VE, 1994;
Wadman I, 1994). Again, the same phenotype is seen in mice and cells with knockout of this
gene (Warren AJ, 1994).
GATA-1 is a zinc-finger transcription factor that binds to the β-globin locus and encodes the
GATA-1 protein (Pevny L, 1991). Its expression is limited to erythroid, eosinophil, mast,
megakaryocyte lineages and multipotent progenitors (Martin DI, 1990; Romeo PH, 1990; Zon
LI, 1993; Zheng J, 2006). The phenotype seen in adult mice without GATA-1 resembles that of
aplastic red blood cell crisis in humans whereas in mouse embryos this leads to in utero death
(Gutierrez, 2008). Constitutive GATA-1 mutations that prevent the interaction between its
cofactor FOG-1 result in different types of anemia (Arnaud L, 2010). Germline mutations that
truncate N-terminal GATA-1 protein have been associated with inheritance of bone marrow
failure, by impairing erythroid differentiation (Sankaran VG, 2012).
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Figure 1.2: Primitive and Definitive Erythropoietic Pathways
HSC = Hematopoietic Stem Cell, BFU-E = Burst-Forming Unit Erythroid, CFU-E = Colony Forming
Unit-Erythroid, ProE = Proerythroblast, BasoE = Basophilic erythroblast, PolyE =
Polychromatophilic erythroblast, OrthoE = Orthochromatic erythroblast, Retic = Reticulocyte, EryPCFC = Erythroid Progenitor Colony Forming Cells. Figure adapted from Palis J. Front Physiol. 2014
(Palis 2014).

Unlike GATA-1, GATA-2 is expressed in the yolk sac, fetal liver, bone marrow, spleen and
in progenitor cells (Dorfman DM, 1992; Leonard M, 1993; Visvader J, 1993). For this reason
GATA-2 regulates genes controlling both stem cell/early progenitor cell proliferation and
response to hematopoietic growth factors (Tsai FY, 1994). Heterozygous mutations in the
GATA-2 gene lead to a susceptible immune system (Spinner MA, 2014). CD34+ cells isolated
from aplastic anemic patients had reduced GATA-2 mRNA expression (Fujimaki S, 2001).
A family of transcription factors known as Krüppel-like factors plays important roles in
regulating erythropoiesis. They are further discussed in section 1.4 with the emphasis on KLF1
as this transcription factor is integral to the research presented in the thesis.
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1.2 Hemoglobin of Mice and Men
Hemoglobin is the most abundant protein found in erythrocytes responsible for binding and
transportation of oxygen or carbon dioxide in the bloodstream of vertebrates. Each subunit of
hemoglobin is a globular protein with an embedded heme group. Different kinds of hemoglobin
are present in the blood due to composition of different subunits at different stages of
development.

1.2.1 The α-globin and β-globin Loci
In humans, The α-family globin genes – ζ2 (embryonic), ζ1 (embryonic), α2 (fetal/adult) and
α1 (fetal/adult) reside in the α-globin locus on chromosome 16 (Figure 1.3 A) (Weatherall, 2001;
Zhang et al., 2002). The β-family globin genes are arranged in the order of their developmental
expression pattern 5’- ε (embryonic) - Gγ - Aγ (fetal) - δ - β (adult) – 3’, with the β-globin gene
being expressed last, on chromosome 11 (Figure 1.3 A) in humans (S. Philipsen, 2013; Bank et
al., 1980; Weatherall, 2001; Crossley M, 1993).
Mice do not express a distinct fetal hemoglobin (McConnell SC et al., 2011) as seen in
humans, that is, there is only embryonic and adult hemoglobin synthesized. However, in recent
years, many transgenic mouse models have been generated carrying the human β-globin gene
locus to mimic human hemoglobins for scientific study and are further discussed in section 1.6.3.
The orthologous (to humans) mouse hemoglobins that appear are embryonic ζ2εy2 and ζ2βh12 and
adult α2βmin and α2βmaj. The four β-family globin genes – εy (embryonic), βh1 (embryonic), βmaj
(adult) and βmin (adult) reside in the mouse β-globin locus on chromosome 7 (Noordermeer and
de Laat, 2008). The same α-family globin genes – ζ2 (embryonic), ζ1 (embryonic), α2 (adult)
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and α1 (adult) are present in mice as in humans but on chromosome 11 (Popp, 1981; Tufarelli,
2004).
In humans, embryonic hemoglobin Gower-1 is the first hemoglobin to appear in the very
early stages of embryonic development and consists of two ζ-globin chains and two ε-globin
chains to form the ζ2ε2 tetramer. Embryonic hemoglobin Gower-2 is the next hemoglobin to
appear and is a tetramer of two α-globin and two ε-globin chains to form α2ε2 and is followed by
embryonic hemoglobin Portland which instead of ε-globin has two chains of γ-globin to form the
tetramer ζ2γ2. These three embryonic globins are derived from the embryonic yolk sac and are
expressed in primitive erythropoietic cells. Fetal hemoglobin (HbF) is made in the fetal liver and
consists of two α-globin chains and two γ-globin chains to form the α2γ2 tetramer. HbF replaces
the embryonic globins and predominates the blood hemoglobin for the remainder of fetal
development. Adult β-globin chains arise around the 12th week of development in the bone
marrow leading to the progressive increase of adult hemoglobin (HbA) levels α2β2 and the
accompanying decrease of HBF. At about six months after birth the hemoglobin in human blood
is comprised of 97% HbA, 2% HbA2 and 1% HbF (Figure 1.3 B) (Bank et al., 1980, Weatherall,
2001, Qiu et al., 2008), this shift from predominantly embryonic globin to HbF and then from
predominant HbF to HbA in the bloodstream of humans is termed hemoglobin switching (Figure
1.3 B) and is discussed in more detail under section 1.2.3.
Definitive erythroid cells express the adult β1-and β2-globin genes in mice, and fetal γand adult β-globin genes in humans from the β-globin gene cluster. Whereas, primitive erythroid
cells express the mouse embryonic εy- and βh1-globin genes and the human embryonic ε- and
fetal γ-globin genes from the β-globin gene cluster. The embryonic ζ- and adult α-globin genes
of the α-globin gene cluster is expressed in both types of cells.
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1.2.2 Regulation of β-Globin Genes
In humans, the β-globin genes are regulated by regulatory elements in promoters of each βglobin gene, i.e., CAAT, TATA and CACCC boxes or sequences (Cao and Moi, 2002) and the
locus control regions (LCRs). LCRs are DNA regulatory elements that are responsible for cislinked genes being highly expressed regardless of LCR location within the locus via stabilization
of open chromatin conformation (Grosveld, 1987; Forrester, 1990; Minnie, 1992). The human βglobin locus has an LCR spanning 15 kb located upstream of the ε-globin gene containing 7
DNAse I hypersensitive sites (HS) and controls the differential expression exhibited by the βglobin genes during different stages of ontogeny (Epner, 1992 ; Enver, 1990; Behringer, 1990;
Dillon, 1991; Hanscombe 1991). The active sequences of the βLCR are contained within 7
DNase I hypersensitive sites four designated – 5’ HS1, HS2, HS3 and HS4 and the remaining
three – 3’HS5, HS6 and HS7. Each HS contains DNA-binding elements such as NF-E2, KLF1,
and GATA-1 binding sites which are DNA regulatory elements (Tuan, 1985; Forrester, 1986;
Wijgerde et al., 1995; Noordermeer and de Laat, 2008). Only one β-globin gene can be activated
at one time via joint action between the LCR and promoter regulatory elements. In mice, the two
βLCRs can activate either the two embryonic genes or the two adult genes simultaneously
(Trimborn et al., 1999; Noordermeer and de Laat, 2008). Reasoning for βLCR action as not just
a classical enhancer but as a novel type of regulatory element that controls the entire β-globin
locus’s genetic activity (Gerardo Jiminez, 1992) was explained by the ability of the βLCR to
loop or spatially interact with β-globin genes (Tolhuis et al., 2002).
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1.2.3 Hemoglobin Switching
A phenomenon unique to vertebrates termed hemoglobin switching is studied with the
ultimate goal of treating hemoglobinopathies. Hemoglobin switching in humans is defined as the
change in expression from the predominant embryonic hemoglobin to fetal hemoglobin to adult
hemoglobin during development, i.e., two switches (Figure 1.3 B). In mice and other mammals
there is only one hemoglobin switch, i.e., from the predominant embryonic to adult hemoglobin
during development (Sankaran, 2010; Stamatoyannopoulos, 2005; Kingsley, 2006; Weatherall,
2001). The α-globin chains replace the ζ-globin chains at E12.5 and week 12 in utero of mice
and humans, respectively (Palis et al. 2010). Transcriptional regulators GATA1, KLF1, SOX6
and BCL11A suppress expression of embryonic globin genes (Sankaran, 2009).

1.3 β-globin Gene Cluster Anomalies

1.3.1 β-Hemoglobinopathies
These diseases become manifested following the hemoglobin switch from HbF to HbA because
of decreased synthesis of, absence of, or ineffective β-globin protein production. The most
prevalent β-hemoglobinopathies are sickle cell disease (SCD) and β-thalassemia. Currently the
number of people living with SCD is approximated to be 100,000 in the USA and 200 to 300
million worldwide (CDC, 2017; Piel FB et al., 2013). SCD is an autosomal recessive disorder
caused by a point mutation where glutamic acid (charged amino acid) is substituted by valine
(non-polar amino acid) in the 6th codon of the β-globin gene to form the βs mutant chain. This
forms abnormal sickle shaped erythrocytes in the blood stream under hypoxic conditions which
have difficulty moving through blood capillaries and also reduce oxygen carrying capacity. β-

11

thalassemia is one of the most common genetic diseases in the world with approximately 15,000
afflicted in the USA and 72 million people worldwide having the major form of the disease
(CDC, 2017). There are three types of β-thalassemia based on residual amount of β-globin: βthalassemia minor with β+/β or β/β0; intermedia with β+/β+ or β0/β+; and major with β0/β0, where
β+ is decreased and β0 is absent β-globin protein.
Phenotypes vary significantly in severity with respect to anemia, organ failure and life
span. Due to these reasons, In the 1980s and 90s median lifespan of SCD and thalassemic
patients was between 40 to 50 years (Platt OS, 1994). Current standard medical care for
thalassemia and SCD patients is aimed at alleviating these symptoms through blood transfusions,
iron chelation therapy, treatment with hydroxyurea and/or a combination of these treatments
(Agrawal RK, 2014). Life expectancy of sickle cell patients has only increase to ~50 years
(Chaturvedi, S et al., 2016), thalassemic patients has increased, and now approaches that of
healthy individuals (Diamantidis, M.D. et al., 2016).
Blood transfusions are performed every 3-4 months throughout an affected patient’s life.
This involves a higher expense, risk of acquiring a transmitted infection and/or severe iron
overload. To overcome these issues, iron chelation therapy was developed to remove excess iron
from vital organs, but it is not economical and requires trained, professional personnel, which is
difficult to acquire in those countries where SCD rates are highest. Hydroxyurea is the only
effective drug proven to reduce the frequency of painful episodes seen in SCD patients by 50%.
The known mechanism of action in increasing HbF is inhibition of the enzyme involved in the
reaction transforming ribonucleosides into deoxyribonucleosides, ribonucleotide reductase,
which reduces DNA synthesis overall (Agrawal RK et al., 2014). Inhibited DNA synthesis is a
good thing for a short period of time as in the case of hydroxyurea. One-daily dose of
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Figure 1.3: Human α- and β-Globin Loci and Hemoglobin Switching
In 1.3 A, the α-globin locus on chromosome 16 in humans and the β-globin locus on chromosome 11
in humans is depicted. In B, The synthesis levels of each individual globin protein is shown from time
of conception to adult life, the hemoglobin switch between β- and γ-globin’s can be easily seen. The
corresponding predominant hemoglobin prevalent is shown below the respective time-period of life.
Figure adapted from https://www.studyblue.com/#flashcard/flip/hemoglobintypes/3334284,
accession date: June 19th, 2017.
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hydroxyurea in patients causes periodic erythroid progenitors and erythroid cell stress signals to
be suppressed, which recruits erythroid progenitors that generate erythrocytes with more HbF
than normal (Agrawal RK et al., 2014). It is conjectured that side effects of this drug are due to
its interference with DNA synthesis causing DNA to be susceptible to chromosome breakage
(Mazouzi A et al., 2014). These side effects include but are not limited to neutropenia, bone
marrow suppression, elevation of hepatic enzymes and infertility (Brawley OW et al., 2008;
Agrawal RK et al., 2014).
Currently, the only viable cure for β-hemoglobinopathies is bone marrow transplantation.
Not only is it difficult to find a matching bone marrow donor but it can be complicated by
debilitating graft versus host disease (GVHD) or host versus graft disease (HVGD) and is costly
(Sankaran and Nathan 2010). GVHD occurs when the donor’s bone marrow T-cells reject all of
the recipient’s cells as “non-self” and destroy the recipient’s body. HVGD occurs when the
recipient’s immune system identifies the donor bone marrow as “non-self” and destroys the
transplant tissue. Most patients affected with a β-hemoglobinopathy have normal γ-globin genes
(Gγ, Aγ) and it has been shown that reversing the switch from HbF to HbA ameliorates
symptoms seen (Weatherall BJ et al., 2001). Patients with greater than 20% γ-globin levels of
total β-globin chains require little to no hospital care and suffer no “attacks”. This is why
research to discover pharmacologic induction of HbF is the next step in a potential cure to treat
β-hemoglobinopathies (Trompeter S, 2009; Hankins J, 2009).
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1.3.2 Hereditary Persistence of Fetal Hemoglobin
The sustained expression of fetal hemoglobin into adult life is termed hereditary persistence
of fetal hemoglobin (HPFH). There has been no direct evidence showing adverse effects related
to individuals with HPFH, rather it has been shown to ameliorate symptoms seen in patients
affected with β-hemoglobinopathies (Galanello R et al., 1998). First it was thought that HPFH
was caused by naturally occurring mutations only in the γ-globin gene on the β-globin locus, but
now >50% of all naturally occurring mutations leading to HPFH are due to variants in the βglobin gene, the γ-globin repressor gene BCL11A, the HBSIL-MYB loci and the transcription
factor KLF1 (Thein SL et al., 2009; Borg J et al., 2010).
Variants in the β-globin gene promoter cause β-thalassemia minor along with elevated HbF
(Huisman TH, 1997; Felber BK, 1982). The more common γ-globin mutations causing HPFH
involve small deletions in the 3’ sequences of the γ-globin genes by removing suppressor
elements, like the deletion in the intergenic region between the Aγ and δ-globin genes (Huisman
TH et al., 1974; Gazouli M et al., 2009). Less common are large deletions which bring novel
enhancer elements closer to the γ-globin gene promoters (Anagnou NP et al., 1995) and point
mutations. The XmnI polymorphism is a single nucleotide polymorphism (SNP) C>T at -158
position of the γ-globin promoter with population frequency ranging from 0.32 to 0.35 (Garner C
et al., 2000). A 20% increase in HbF is observed in these heterozygous sickle cell patients as
compared to the heterozygous general population (Bhagat S, 2012). A rarer naturally occurring
point mutation G>A at -117 position of the Aγ promoter displays a 10-20% HbF increase in
heterozygotes (Siegel W et al., 1970).
The human population also has less frequent but naturally occurring HPFH –associated
mutations caused by deletions ranging from 13 nucleotides to 106 kb (EA Traxler et al., 2016;
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Ye L et al., 2016) and by point mutations in the β-globin locus. The overall increase in HbF for
total hemoglobin is quite variable ranging from 2% to 41% (Figure 1.4). Reproducing these
HPFH mutations to reactivate γ-globin gene expression is a relatively new potential therapy
being researched, now possible by in vitro by gene editing (Traxler EA et al., 2016; Ye L et al.,
2016; Hossain MA et al., 2016), though not yet available as therapy. One of the major caveats of
gene editing is off-target mutation induction,
The first case of a KLF1 mutation causing HPFH was studied in a Maltese family and
revealed a nonsense mutation that ablated the DNA binding domain of KLF1 on chromosome
19, termed the p.K288X mutation (Siatecka M, 2011). Only carriers or heterozygotes of the
K288X mutation showed increased HbF levels in the range between 3.3% – 19.5%. Other KLF1
mutations involved in HPFH were associated with variable but significantly increased ranges of
HbF (Borg J et al., 2010; Borg J et al., 2011). Compound heterozygotes of reduced function and
truncating loss of function display up to 40% HbF of total hemoglobin (Perkins AC et al., 1996;
Perkins AC et al., 2016). The presence of a heterozygous dominant KLF1 mutation c.973G>A
was associated with a profound dysregulation of globin gene expression termed congenital
dyserythropoietic anemia (CDA) as well as HPFH of ~35% HbF of hemoglobin (Arnaud L et
al., 2010).
BCL11A, c-MYB and other γ-globin gene repressors were once considered as potential
targets for reactivation of γ-globin gene expression. However, these repressors have been linked
to malignancies in humans (Lahortiga I et al., 2007; Satterwhite E et al., 2001, S. Philipsen,
2013). Also, there is a distinct advantage in identifying direct or indirect erythroid-specific
repressors (like KLF1) because only erythrocytes would be affected and any other cell types
would remain undisturbed (Funnell AP et al., 2015).
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1.4 Krüppel-like Factor 1 (KLF1)

1.4.1 KLF Family
KLF1, discovered in 1992, is the first of 17 transcription factors in the Krüppel-like family
(Miller IJ, 1993; Turner J, 1999). All KLFs are involved in embryonic and cellular processes and
have three characteristic Cys2-His2 zinc finger DNA-binding proteins at their C-terminus
(Figure 1.5) which share homology to the fruit fly regulatory patterning protein – Krüppel
(McConnell BB et al., 2010). The C-termini are similar in all KLFs and the N-termini vary
allowing different

Table 1.1: Single Point and Deletion Mutations in the β-globin Locus Associated with
HPFH (Adapted from Carrocini, G.C.D.S et al., 2011)
Mutation Type
Single Point

Mutation
-110 (A -> C) γG (Czech)
-114 (C -> G) γG (Australian)
-114 (C -> T) γG (Japanese)
-175 (T -> C) γG
-202 (C -> G) γG
-114 (C -> T) γA (Georgia)
-117 (G -> A) γA (Black-Greek)
-117 (G -> A) γA (Greek-Italian)
-158 (C -> T) γA (Greek)
-175 (T -> C) γA(Black)
-195 (C -> G) γA (Brazilian)
-196 (C -> T) γA (Italian)
-198 (T -> C) γA (British)
-202 (C -> T) γA

% of HbF
0.6% – 0.8%
8.6%
11.0% - 14.0%
22.1%
18.0% - 23.5%
4.7% - 4.8%
10.9% - 15.9%
7.1% - 19.0%
2.9% - 5.1%
36.7% - 38.5%
4.5% - 7.0%
12.0% - 16.0%
1.8% - 13.0%
1.6% - 3.9%

Deletional

HPFH-1 (Black)
HPFH-2 (Ghanian)
HPFH-3 (Indian
HPFH-4 (Italian)
HPFH-5 (Italian
HPFH-6 (Thai)

21.4% - 28.2%
21.6% - 27.2%
21.6% - 23.6%
21.0% - 30.0%
16.0% - 20.0%
17.2% - 20.0%
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KLFs to act on other genes to repress, activate or both. KLF2, KLF3 and KLF8 are other KLFs
that play roles in erythropoiesis. Activity of both KLF3 and KLF8 is mainly transcriptional
repression of γ-globin gene expression and other genes due to recruitment of C-terminal Binding
Protein co-repressors CtBP1 and CtBP2 (Turner J, 1998; Turner J, 2003; Eaton SA, 2008). The
mild phenotype observed in both KLF3-/- and KLF8-/- mice shows that KLF3 and KLF8 are not
integral to erythropoiesis (Funnell et al. 2012; Sue et al. 2008; Funnell et al. 2013). KLF1
positively regulates KLF3 and KLF8 in erythroid cells and KLF3 represses KLF8, forming a
transcriptional network that may be important for the normal progression of erythropoiesis
(Eaton et al. 2008; Funnell et al. 2007). KLF2 directly binds the βLCR, the βYAC transgenic
mouse ε-globin and γ-globin gene promoters, and the mouse embryonic εy- and βh1-globin gene
promoters suggesting it could have a similar role to KLF1 in regulating embryonic and fetal
erythropoiesis (Alhashem YN et al., 2011; Vinjamur DS et al., 2014). KLF2 is also essential for
embryonic erythropoiesis, erythroid precursor maintenance and progression of erythroblasts from
G to S1 phase of the cell cycle (Vinjamur DS et al., 2014).

1.4.2 Structure, Expression and Functions
KLF1 resides on chromosome 19 and 8 in humans and mice, respectively. The KLF1 protein
has three zinc finger domain proteins – ZF1, ZF2 and ZF3 present at the C-terminus and two
short transactivation domains – TAD1 and TAD2 present at the N-terminus (Mas C et al., 2011;
Raiola L, 2013). The protein has three exons of which parts of exons 2 and 3 encode the zinc
finger domain proteins.
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Within the bloodstream, expression of KLF1 mRNA is first seen in E7.5 of mouse
extraembryonic mesoderm of the yolk sac (Southwood, 1996), is upregulated by E8.5 and then
gets downregulated by E12.5 (Isern J, 2010). These phases of KLF1 mRNA expression levels are
verified by observation of KLF1 ablated (KLF1-/-) mouse embryos; they become anemic around
E11 and ultimately die in utero at E16 (Nuez et al., 1995; Perkins AC, 1995; Magor GW et al.,
2015; Hodge D et al., 2006; Pilon AM, 2008). Definitive and primitive KLF1-/- erythroid cells at
E15 show abnormal morphology, reduced β-globin chain expression and dysregulation of
embryonic βh1- and εy-globin genes (Perkins AC, 1996; Basu et al., 2007; Hodge D et al.,
2006). This parallels the dependence on the hemoglobin switch from embryonic hemoglobin in
the yolk sac to fetal hemoglobin in the fetal liver (Perkins AC, 1995). Expression is seen in both
types of erythropoietic cells during embryonic development yet is contained to only the fetal
liver, spleen and bone marrow in definitive erythropoietic cells during the later fetal and adult
stages of development (Southwood 1996; Miller IJ, 1993). A significant amount of KLF1 is
found in the cytoplasm of cells throughout erythropoiesis (Quadrini KJ, 2008; Schoenfelder S,
2010). The first cells to express KLF1 are uncommitted erythroid hematopoietic cells (Frontelo
et al. 2007), then at low levels multipotent hematopoietic progenitors (MPP) and common
myeloid-erythroid progenitor (CMP). KLF1 is expressed at higher levels in CMPs than in the
common megakaryocyte-erythroid progenitor (MEP) (Frontelo et al. 2007; Lohmann and Bieker
2008).
The multitudes of functions performed by KLF1 are quite vast but are all ultimately
erythropoiesis-related. Hence, Erythroid KLF (EKLF) was the previous name given to KLF1 and
therefore, mainly functions to transcribe globin and non-globin erythroid-expressed genes
(Myers RM et al., 1986; Miller IJ et al., 1993; Hartzog GA et al., 1993). KLF1 is responsible for
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proliferation of erythroid cells in both primitive and definitive erythropoiesis, though it is present
in a lower amount in primitive erythropoietic cells; it is needed for embryonic erythropoiesis
(Alhashem et al. 2011; Zhou et al. 2006). These functions include activating the PKLR gene
which produces Pyruvate Kinase protein and coordinating the expression of cytoskeletal and
membrane proteins, iron processing proteins and heme synthesis enzymes (Drissen et al. 2005;
Hodge et al. 2006; Nilson et al. 2006; Pang et al. 2012). The iron processing proteins like TFR2,
and ABCB10 (Magor GW, 2015; Tallack MR, 2010) and heme synthesis enzymes such as
ALAS2, ALAD, HMBS (Drissen R et al., 2005; Pilon Am et al., 2008; Desgardin AD et al.,
2012). It is also required for normal histone modifications and to generate DNAseI
hypersensitivity in the promoters of β-globin locus genes to maintain normal chromatin structure.
This is done by recruiting histone acetyl transferases (HATs) (Mas C, 2011; Zhang W, 1998), a
H3.3 chaperone (Soni S, 2014) and a chromatin remodeling complex (Zhang W, 1998; Bottardi
et al., 2006; Armstrong JA, 1998; Kadam S, 2000). It is also responsible for chromatin looping
which activates adult β-globin gene expression by bringing the βLCR in closer proximity to the
β-globin gene promoter (Nuez B, 1995; Perkins AC, 1995; Drissen R, 2004).

Figure 1.4: Structure of the KLF-Family Members
Adapted from Vinjamur DS Dissertation, 2014

KLF1 regulates the hemoglobin switch, it was seen that KLF1-/- mice carrying the human βglobin locus transgene affected KLF1 binding in the promoter region of the γ- and β-globin
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genes (Feng WC, 1994; Donze D, 1995, Wijgerde M, 1996; Perkins AC, 1996). While β-globin
gene expression is positively regulated by KLF1, regulation of γ-globin gene expression is more
complicated. KLF1 positively regulates γ-globin expression while also negatively regulating it
by upregulating γ-globin gene repressors BCL11A and SOX6 (Borg J, 2010; Zhou D, 2010;
Tallack MR, 2013).
It was shown in 2007, 2008 and 2009 that KLF1 -/- erythroid cells cannot move from the
G1- to S- phases of the cell cycle as KLF1 also regulates cell cycle genes E2f2 and p18INK4c
(Tallack, 2007; Pilon et al. 2008; Tallack et al. 2009). Another significant function KLF1 makes
is its requirement in co-association of KLF1-regulated genes in nuclear transcription factories,
making KLF1 a global regulator in gene expression (Schoenfelder S, 2010).
The transcriptome pattern observed in KLF1 -/- mice showed that KLF1 rarely acts as a
transcriptional repressor in vivo (Hodge D et al, 2006; Tallack MR et al., 2012), and is indirectly
responsible for erythrocyte formation by coordinating expression of a multitude of genes
involved in erythrocyte production (Magor GW et al., 2015). KLF1 regulates cell surface
proteins such as aquaporins that are involved in erythrocyte membrane integrity. These surface
proteins also interact with developing erythroid cells and macrophages in the erythroblastic
islands during definitive erythropoiesis (Arnaud L et al., 2010; Singleton BK et al., 2008; Xue L
et al., 2014). More recently, KLF1 has been implicated in regulating >20 genes associated with
cell signaling and autophagy. KLF1 also indirectly represses γ-globin gene expression and is
further discussed in section 1.5.1
In summary, over 120 genes and their respective proteins involved in cell division,
cytokinesis, cytoskeleton formation, autophagy, cell signaling, heme and globin formation, etc.
are KLF1-dependent (Magor GW et al., 2015).
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1.4.3 Variants
KLF1 is vital for normal erythropoiesis to occur and as discussed earlier, total ablation
results in in utero death. It is therefore important to understand the types of KLF1 variants as
they are responsible for a wide range of red cell phenotypes like dysregulated globin expression,
hydrops fetalis, non-spherocytic anemia, congenital dyserythropoietic anemia (CDA) and
pyruvate kinase deficiency. These variants that alter the protein-coding sequence of KLF1can be
categorized into four groups (Figure 1.6).
Variants in class 1 are neutral polymorphism missense mutations occurring outside of the
DNA-binding domain. In total there are 11 of these variants with a few occurring in
tranactivation domain 1 and 2 (TAD1 and TAD2).
Class 2 variants are hypomorphic missense mutations or small in-frame deletions within the
DNA-binding domain with reduced function. The potential mechanisms of class 2 variants
include reduced affinity to all if not most in vivo DNA-binding sites, off-target interactions and
altered protein-protein interaction (Perkins AC et al., 2016). Variants in class 3 are stop codon or
frame shift variants resulting in truncated loss-of-function KLF1 protein (Perkins AC et al.,
2016). These classes have the most number of total variants because compound heterozygotes
carry at least one or the other on one allele or both classes on two alleles. Compound
heterozygotes of class 2 and 3 variants are characterized by HPFH with approximately 30% HbF
of total hemoglobin in the blood of β-thalassemic patients (Borg J, 2010; Satta S, 2011; Satta S et
al., 2012; Huang J et al., 2015).
When KLF1 expression in the blood is low it causes the phenotype of the individual to have
the blood group In(Lu) or inhibitor of Lutheran, patients that present with this blood type
normally have one normal allele and a class 2 or class 3 variant (Singleton BK, 2008; Helias V,
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2013). The KLF1 variant K288X causing HPFH in the Maltese family discussed in section 1.2.3
is in fact a class 3 variant (Borg J et al., 2010). Therefore carriers of class 2 or 3 variants express
the In(Lu) and the HPFH phenotypes. Screening for these variants is done by detecting high
levels of HbA2 or α2δ2 (Liu D et al., 2014; Perseu L et al., 2011) or elevated zinc protoporphyrin
(ZnPP), an inhibitor of the enzyme that degrades heme, in the presence of normal iron (Satta S et
al., 2011; Huang J et al., 2015), i.e., when iron levels are normal but is not incorporated into
heme. Class 2 and 3 Compound heterozygotes exhibit low pyruvate kinase levels and exhibit
premature erythrocyte destruction (Viprakasit V et al., 2014; Huang J, 2015). An example is
when Class 2 variant p.A298P is inherited along with a class 3 variant to give the severe NSHA
phenotype.

Only two variants are categorized under Class 4, which are dominant and the most
Figure 1.5: KLF1 Functional Domains and Variants
The two transactivation domains (TAD) located at the N-terminus and the three zinc fingers (ZF)
located at the C-terminus from the DNA –binding domain are shown. Variants are color-coded: Class
1 is green, class 2 is blue and class 3 is red. The blue highlights are histidine and cysteine residues
involved in zinc coordination, yellow highlights are residues that are KLF1-binding sites. Adapted
from Perkins AC, 2016, Blood.

phenotypically severe of all KLF1 variants. This human KLF1 variant p.E235K causes CDA IV
by altering the ZF2 of KLF1 and is generally appears de novo (Arnaud L et al., 2010; Jaffray JA,
2013; Singleton BK, 2009). The second variant also expresses a similar phenotype to CDA IV
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patients and is seen in mice as a missense mutation p.E339D in ZF2 of KLF1that causes in vivo
degenerate DNA binding specificity of KLF1 and is further discussed under the neonatal
mutation (Nan) mouse model in section 1.6.3. (Huang S, et al., 2016; Planutis A et al., 2017;
Heruth DP, 2010; Siatecka M, 2010). Therefore, most monoallelic KLF1 mutations are
associated with benign phenotypes which include increased levels of HbF and HbA2 (Liu D,
2014).
The first human KLF1-null neonate ever observed was reported in 2015 which is
contradictory to the fetal lethality observed in KLF1 -/- mouse embryos (Perkins AC et al.,
1995; Singleton BK et al., 2009; Magor GW et al., 2015). The child in question was born with
>70% HbF, brain damage, jaundice and fetal distress all of which required blood transfusions
from time of birth. This phenotype was even more severe than phenotype seen in CDA IV from
the class 4 variants and termed hydrops fetalis (Magor GW et al. 2015). The parents who were
phenotypically normal carried class 3 KLF1 variants – a frameshift p.R319Efs34X variant and a
stop codon p.W30X variant. However, the altered gene expression throughout the transcriptome
in the human was similar to the expression seen in KLF1 null mice (Magor GW et al., 2015;
Hodge D et al., 2006; Pilon AM et al., 2008). It is suggested that persistence of HbF (HPFH) was
the only explanation for survival of the KLF1-null neonate.
It makes sense that rates of KLF1 variants are higher than previously thought since KLF1 is
the positive regulator of hemoglobin switching (Borg J et al., 2010; Wijgerde M et al., 1996) and
prevention or reversal of hemoglobin switching is beneficial to those affected with a form of βhemoglobinopathy (Weatherall DJ et al., 2001). Another reason for high prevalence of class 2
and 3 variants is the fact that they change the basic morphology and activity of erythrocytes
making it more difficult for malarial parasites to propagate. For example, southern Chinese
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populations have a very high incidence rate of class 2 and 3 variants combined at ~1.3%. Coinheritance of KLF1 variants and hemoglobinopathies is common (Yu LH et al., 2015; Liu D et
al., 2014). Although DNA sequencing has not been performed in Mediterranean, south east Asia
and Africa, it can be assumed that incidence rates of class 2 and 3 variants are high as these are
areas where hemoglobinopathies are endemic (Viprakasit V et al., 2014; Perseu L et al., 2011;
Satta S et al., 2011; Yu LH et al., 2015; Tepakhan W et al., 2015).

1.4.4 Regulation and Binding
Mouse genome-wide analysis indicates that the core 9 base pair DNA consensus sequence
that KLF1 binds to is 5’ CCM CRC CCN 3’ (R: A/G, M: A/C) (Siatecka et al., 2010; Siatecka
M, 2011; Feng et al., 1994; Miller and Bieker 1993; Tallack et al.,2010; Pilon Am et al., 2011).
KLF1 regulates β- and γ-globin genes by binding to the sequences CCACACCCT at -90 in the βglobin promoter, and CTCCACCCA in the γ-globin promoter, with greatest affinity for the βglobin promoter (Miller and Bieker, 1993; Donze et al., 1995; Zhang and Bieker, 1998; Dang et
al., 2000; Perkins et al., 1999). In mice, KLF1 occupies less than 0.5% of potential KLF1binding motifs in progenitor and erythroblast chromatin, similar to that seen in GATA1 and
TAL1 (Cheng Y et al., 2009; Fujiwara T et al., 2009; Kassouf MT et al., 2010). Of the 945
progenitor- and erythroblast-specific sites occupied by endogenous KLF1, the majority are
distant from any known gene which may be explained by association with organization of
chromosomal neighborhoods and transcriptional elongation (Chien R et al., 2011; Lee HY et al.,
2011).
Binding of KLF1 in the β-globin locus of mice at E10.5 and E11.5 showed that KLF1 is
enriched at the εy-, βh1- globin gene promoters and enriched at the mouse 5’HS2 in the βLCR.
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In transgenic βYAC mice with the human β-globin locus, KLF1 was enriched at human 5’HS3
and 5’HS2 sites in the βLCR and also enriched at the γ-globin gene promoter. KLF1 binds to all
mouse and human embryonic and fetal gene promoters and to the βLCR as shown by ChIP
assays (Alhashem YN et al., 2011; Alhashem YN, Dissertation, 2012.). This evidence suggests
KLF1 acts directly as a positive regulator of human and mouse embryonic and fetal genes during
embryonic erythropoiesis, which is in contrast with research that supports an indirect negative
role for KLF1 in regulating γ-globin gene expression (Alhashem et al., 2011; Perkins et al.,
1996; Wijerde et al., 1996) (Figure 1.7).
Examining how KLF1 affects histone modifications in wildtype and βYAC transgenic mice
on the globin genes we see that, at E10.5, the mouse εy- and βh1 genes and human ε- and γglobin mRNAs were enriched with H3K9Ac and H3K4me3. Specifically at the βLCR the
amount of H3K9Ac and H3K4me3 is generally less than at the globin genes, but is enriched
compared to IgG. This is validated when there is a significant reduction in enrichment of
H3K9Ac and H3K4me3 in mouse and human embryonic and fetal genes upon ablation of KLF
(Alhashem YN et al., 2011; Alhashem YN. 2012). This shows that H3K9Ac is only associated
with actively transcribed globin genes in native embryonic erythroid cells. Based on this data, it
can be said that KLF1 acts positively on γ-globin gene expression (Alhashem et al., 2011).
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Figure 1.6: KLF1 Binds the Mouse and Human β-globin Loci in Primitive Erythroid
Cells
ChIP assays were performed on E10.5 A) or E11.5 B) primitive erythroid cells collected
from peripheral blood of normal mice or βYAC transgenic mice. A) In transgenic mice,
KLF1 binds HS3 site, HS2 site and γ-globin promoter region in significantly. B) In
transgenic mice, KLF1 binds HS3 site, HS2 site, ε-globin and γ-globin-promoters
significantly. A) & B) Binding of KLF1 vs. control IgG shows that KLF1 binds HS2 site, Eγ
promoter and the βh1 promoter regions in normal mice significantly when compared to IgG.
Adapted from Alhashem YN et al., 2011 J. Biol. Chem. (Alhashem YN et al., 2011)

27

1.5 The γ-Globin Gene Suppression Network

Figure 1.7: The γ-globin Suppression Network
1.5.1 KLF1
The role of KLF1 can interestingly be both negative and positive on γ -globin gene regulation
in human and mouse fetal erythroblasts. Previous studies have shown that lentiviral knockdown
of KLF1 increases the amount of γ-globin while decreasing the amount of BCL11A (Miller IJ et
al., 1993; Pilon AM et al., 2008). KLF1 directly regulates direct γ-globin repressor genes KLF3,
KLF8 (Funnell et al., 2013) and BCL11A (Nuez Beatrice et al., 1995; Zhou D et al., 2010). This
might indicate that KLF1 directly regulates other γ-globin repressor genes. Human CD34+
precursor cells with a 40-70% KLF1 knockdown show elevated γ-globin transcript levels, but
with a > 80% KLF1 knockdown the γ -globin mRNA levels remain normal (Vinjamur DS, 2014;
Vinjamur DS et al., 2016). This is termed the threshold amount, which is a residual amount of
KLF1 needed by the cell to induce -globin above normal amounts (Figure 1.9) (Vinjamur DS,
2014; Vinjamur DS et al., 2016).
28

1.5.2 BCL11A
One of the major γ-globin repressor genes discovered in primary human erythroid progenitor
cells and transgenic βYAC mice was B-cell Lymphoma/Leukemia 11A (BCL11A) (Sankaran
VG, 2008; Zhou D, 2010; Borg J, 2010; Vinjamur DS, 2014). The mechanistic action of
BCL11A is as follows: It interacts with lysine-specific demethylase 1 (LSD1) and the
corepressor element-1 silencing transcription factor (CoREST) complex to silence γ-globin gene
in adult erythroid cells (Xu J et al., 2013). The BCL11A-associated protein, DNA
methyltransferase 1 (DMNT1), silences HbF in primary human adult erythroid cells (Xu J et al.,
2013). Knockdown of KLF1 in both human and mouse adult erythroid progenitors significantly
decreases BCL11A levels with an accompanied increase in ratio of γ-globin/β-globin (Zhou D et
al., 2010). This suggests KLF1 indirectly represses γ-globin and directly upregulates β-globin.
Adult KLF1 KO/WT mice showed a higher percentage of reticulocytes as compared to BCL11A
CKO/CKO which has mild anemia. However the percentage of reticulocytes increased and
anemia was seen to be more pronounced in compound heterozygotes. The γ-globin expression
levels were high during fetal development but decreased in adult KLF1::BCL11A mutant mice,
though these levels were still higher than adult wildtype mice (Esteghamat F et al., 2016).
Targeting both KLF1 and BCL11A leads to severe anemia and increased percentage of
reticulocytes. This is why targeting BCL11A along the KLF1 axis as a therapeutic approach to
increase HbF levels in β-hemoglobinopathic patients is not feasible (Sankaran VG et a;, 2009;
Sankaran VG et al., 2008; Borg J et al., 2010; Zhou D et al., 2010). Knockdown or knockout of
BCL11A causes some concern as BCL11A is expressed during embryonic development and after
birth in the central nervous system for neuronal differentiation and morphogenesis and is an
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unlikely target for novel therapeutics in treating hemoglobinopathies (Bauer et al., 2012; Leid M
et al., 2004; Kuo TY et al., 2010; John A et al., 2012).

1.5.3

LRF

The Leukemia/Lymphoma-related factor or zinc finger and BTB domain containing 7A
(ZBTB7A) acts as a proto-oncogene via repression of the p19Arf tumor suppressor (Maeda T et
al., 2005). Only recently was LRF found to be another potent silencer of γ-globin gene
expression (Masuda T et al., 2016). Transgenic βYAC mice and HUDEP-2 cells with the LRF
KO showed upregulated γ-globin gene expression ranging from 23.6 – 35.9% as LRF binds the
β-globin gene and also binds immediately downstream of the human HBG1 gene region. It is
assumed that loss of LRF from this region facilitates long-range interaction between the γ-globin
loci and the βLCR leading to γ-globin reactivation and β-globin downregulation (Masuda T et
al., 2016; Tolhuis B et al., 2002). The HUDEP-2 cells lacking either LRF or BCL11A express a
50–60% increase in HbF protein levels determined by HbF over sum of HbF and HbA present as
compared to control. But HbF amounts of > 95% are seen in double knockout cells, suggesting
that the majority of γ-globin silencing activity is comprised of BCL11A and LRF in adult
erythroid cells (Smith EC et al., 2016; Masuda T et al., 2016). LRF has a vast set of functions
beyond erythropoietic development which makes this gene an unlikely target for treating βhemoglobinopathies (Maeda T et al., 2007; Maeda T et al., 2009).
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1.5.4 The DRED Complex
The direct repeat erythroid-definitive (DRED) complex is assumed to be a repressor complex
that binds with high affinity to direct repeat elements of the human embryonic ε- and fetal γglobin promoters, as well as to the murine embryonic εy- and βh1-globin promoters (Cui S. et
al., 2011; Tanabe O et al., 2002). The complex is comprised of four subunits: the nuclear orphan
receptors TR2 and TR4, the DNA methyltransferases (DNMT1) and the lysine-specific
demethylase KDM1A or LSD1. This thesis focuses on the LSD1 subunits which will be
discussed in detail.
Histone demethylase lysine-specific demethylase 1 (LSD1) is shown to interact with
BCL11A in proteomic analysis as mentioned in section 1.5.2 and the TR2/TR4 subunits of the
DRED complex (Xu J et al., 2013). Two specific LSD1 inhibitors namely, Tranylcypromine
(TCP) and RN-1, induced γ-globin gene expression in human erythroid progenitors and a sickle
cell model (Shi L et al., 2013; Rivers A et al., 2015; Cui S et al., 2015). Findings indicate that
induction of HbF upon LSD1 knockdown or knockout is associated with impaired erythroid
differentiation and induction is lower than induction achieved by knockdown or knockout of
BCL11A (Xu J et al., 2013).

1.5.5 The NuRD Complex
The nucleosome remodeling and deacetylase (NuRD) complex is the only known group of
proteins coupling both histone deacetylase and chromatin remodeling ATPase activities to
mainly be involved in transcriptional repression (Xue Y, 1998; Zhang Y, 2010; Denslow SA,
2007). The complex is comprised of seven subunits: the methyl-CpG-binding domain protein
MBD2 or MBD3, chromodomain-helicase-DNA-binding protein CHD3 (Mi2α) or CHD4
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(Mi2β), histone deacetylase core proteins HDAC1 and HDAC2, MTA1 or MTA2 or MTA3
which ae the metastasis-associated proteins and the histone-binding proteins RbAp46 and
RbAp48 (Feng Q et al., 2001). This thesis focuses on the two NuRD subunits Mi2β and MBD2
which will be discussed in detail.
MBD2 is part of the larger MCBP family responsible for recognizing and directly binding to
DNA sequences with methylated cytosines in CpG islands leading to transcriptional repression,
including that of γ-globin (Rupon JW et al., 2006; Gnanapragasam MN et al., 2011; Rupon JW et
al., 2011; Nan X, 2001; Wade PA, 1999; Feng Q 2001). Transgenic βYAC MBD2 null mice
show higher γ-globin expression levels at E14.5 and E16.5 compared to wildtype, but MBD2 has
not been shown to bind the γ-globin gene promoter (Rupon JW et al., 2006). This indicates that
silencing of the γ-globin gene in adult erythroid cells in mice and human CD34+ cells isolated
from umbilical cord blood (discussed in section 1.6.1) is indirectly mediated by the MBD2NuRD complex via methylation (Rupon JW et al., 2006; Gnanapragasam MN et al., 2011). P66α
and MBD2 coiled-coil interaction, found in the MBD2-NuRD complex, facilitate the recruitment
of CHD4/Mi2β to competitively silence the globin genes through DNA methylation in both
mammalian and chicken erythroid cells (Gnanapragasam MN et al., 2011; Amaya MD et al.,
2013).
CHD4/Mi2β is expressed in hematopoietic stem cells and precursors of myeloid, erythroid
and lymphoid lineages (Kim J et al., 1999). It acts to repress globin genes as a subunit in the
NuRD complex or to specifically repress γ-globin gene expression as a member of the GATA1FOG-1-Mi2 complex (Williams CJ et al., 2004; Costa Fc et al., 2012). Mi2β is the largest NuRD
protein and is solely responsible for chromatin remodeling function of NuRD (Amaya M, 2013;
Xu J et al., 2013). It is the major functional component of the γ-globin gene repressor
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MBD2/NuRD complex and disruption between p66α and MBD2 interaction displaces both
MBD2 and Mi2β from the complex, causing γ-globin gene expression (Gnanapragasam et al,
2011). Knockdown of Mi2β induces higher expression of γ-globin gene than do knockdowns of
the MBD2 or GATA-1-FOG-1-Mi2 complexes. Mi2β knockdown is also associated with
reduced expression of KLF1 and BCL11A in murine CID cells, human primary erythroid cells,
HUDEP-2 cells and βYAC mice independent of the MBD2/NuRD complex (Borg J et al., 2010;
Zhou D et al., 2010; Sankaran VG et al., 2009; Amaya M et al., 2013).

1.5.6 c-MYB
The transcription factor c-MYB is highly expressed in immature hematopoietic cells and
downregulated during differentiation (Bianchi E et al., 2010). Analysis of transcription factor cMYB transfected K652 clones demonstrated that c-MYB negatively regulates production of HbF
(Jiang J et al., 2006). C-MYB knockout in mice and human CD34+ erythroid precursor cells
result in in utero death and presence of only mature megakaryocytes and macrophages, whereas,
knockdown results in perturbed erythropoiesis differentiation (Emambokus N et al., 2003.
Mucenski ML et al., 1991). It was shown that c-MYB binds to the promoter and transactivates
expression of KLF1 through chromatin immunoprecipitation and luciferase assays (Bianchi E et
al., 2010). Cells overexpressing KLF1 had partially rescued erythropoiesis caused by silencing of
c-MYB. This transcription factor plays a key role in regulating stem cells of the bone marrow,
colonic crypts and neuronic region in adults. But tinkering with c-MYB is likely to adversely
affect hematopoiesis and erythroid differentiation as c-MYB potentially have been implicated in
human malignancy, and several animal species transplanted with c-MYB-deficient cells died
from different forms of leukemia (Ramsay RG et al., 2008).
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1.6 Model Systems Used in Studying γ-globin Gene Regulation
Over the decades many different in vitro, in vivo and ex vivo models have been used to study
erythropoiesis.

1.6.1 Immortalized Human Cell Lines
Cell lines in the erythropoietic field are often used to study biological processes over their
primary cell counterparts because primary erythropoietic precursor cells are difficult to culture,
maintain and manipulate. Therefore experiments can also be performed using hematopoietic
progenitor cell lines such as the human erythroleukemic K652 and HEL, and mouse MEL cell
lines and the more recent immortalized erythroid progenitor cell lines HUDEP and HiDEP
(Lozzio and Lozzio et al., 1975; Friend et al., 1957; Kurita Ryo et al., 2013). The main
disadvantages to using the erythroleukemic cell lines is that any results seen may be due to the
abnormal chromosomes present inherently in the cell line. It must always be kept in mid that
when interpreting results from immortalized cell samples you must be careful as cell lines do not
always accurately replicate the primary cells (Kaur G, 2012).
The first erythroid progenitor cell line termed murine erythroleukemia (MEL) was derived
from the spleens of Friend virus complex infected mice immortalized by infecting mouse splenic
cells with a virus (Friend et al., 1957; Antoniou et al., 1991). Less than 1% of the MEL cells
spontaneously differentiate and so induction of differentiation to express mouse adult
hemoglobin α2βmaj2 was performed by treatment with dimethyl sulfoxide (DMSO) (Friend et al.,
1971; Antoniou et al., 1991).
K652 cells were established from an erythroleukemic patient in a blast crisis (Lozzio and
Lozzio, 1975). These cells are non-adherent, rounded and have two reciprocal translocations the
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bcr:abl fusion gene (Philadelphia chromosome) present on chromosome 22 and the translocation
between long arm of chromosome 15 with 17 (Lozzio et al., 1975). Deacytylase activity induces
cell differentiation into mature erythrocytes, monocytes or macrophages (Duncan MT, 2016).
The erythroid cells formed upon induction of differentiation exhibit an embryonic/fetal pattern of
globin gene expression, rather than expressing adult hemoglobin, which is one of the major
disadvantages of using these cell lines.
The human erythroleukemia (HEL) cell line was first established in 1982. These cells have
induced and spontaneous production of mainly G- and A-γ chains. Expression of the β- and εglobin chains is negligible. For some time, this cell line was useful in research studying erythroid
cell differentiation and differential globin gene expression. HEL cells were derived from the
peripheral blood of a Hodgkin’s patient with erythroleukemia. Cells resemble large abnormal
proerythroblasts with increased frequency of polyploidy (Martin P et al., 1982).
The most recent cell line to be established is the human umbilical cord blood-derived
erythroid progenitor (HUDEP) cell line from three different cord blood samples termed HUDEP1, HUDEP-2 and HUDEP-3. A tet-inducible HPV16-E6/E7 transgene lentivirus was used to
immortalize umbilical cord blood CD34+ cells, by inhibiting p53 and retinoblastoma tumor
suppressor proteins (Kurita R, 2013; Münger K, 2002). The differences between the three
HUDEP cell lines arise from variation in expression of β-globin genes. HUDEP-1 and -3 are
characteristically more fetal-like by predominantly expressing γ-globin. Whereas, the HUDEP-2
cell line most closely resemble adult erythroid cell pattern based on β-globin gene and γ-globin
repressor BCL11A expression. Development of this system has made studies on adult
erythropoiesis using immortalized cell lines possible for the first time (Canver MC et al., 2015;
Masuda T et al., 2016; Traxler EA et al; 2016).
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1.6.2 Primary Human Cells
Many dependable, refined methods have been developed over the years for isolation of
fetal or adult hematopoietic CD34+ precursor cells from human umbilical cord blood, peripheral
blood and bone marrow. They have become powerful tools in studying γ-globin gene repression.
The main idea is to expand these few progenitor cells to obtain a large number of erythroid cells
(Migliaccio et al., 2002). These methods have become very popular because the CD34+ cells can
be easily in vitro differentiated along an erythroid pathway, while simultaneously performing
knockdown of a gene of choice. The use of lentiviral vectors that express small hairpin RNA
(shRNA) is an efficient method to downregulate genes and hence gives the researcher more
flexibility to perform their experiments. The more recent methods to isolate CD34+ cells from
human umbilical cord blood, bone marrow or peripheral blood are considered the best available
cellular model of erythroid development (Migliaccio et al., 2002; Giarratana et al., 2011). The
expression of the active form of BCL11A is negligible in these cells and (Sankaran VG, 2008).
The drawbacks lie in their relatively limited lifespans and terminal erythroid differentiation while
also maintaining cell viability (Ginder GD, 2015).

1.6.3 Mouse Models with modified KLF1
The processes of primitive and definitive erythropoiesis are very similar in humans and mice
which make using mice to perform in vivo studies on research in β-hemoglobinopathies, the
global role of KLF1, membrane skeleton protein functions and regulation of human β-globin
genes plausible (Peters LL et al., 2001). For this reason mutant, transgenic mouse and knockout
mouse models have been developed.
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In 1992, the first mouse model carrying the entire human β-globin locus was developed with
ligation of two cosmid constructs (Strouboulis J et al., 1992), which is a vector that can only
carry DNA fragments ranging from 37 to 52 kb. A year later with the advent of yeast artificial
chromosomes (YAC), which is a vector that can carry DNA fragments ranging from 100 to 1000
kb, the βYAC transgenic mice were developed (Gaensler KM et al., 1993; Peterson KR et al.,
1993). These models express human globin genes in a manner that resembles the expression if
endogenous mouse genes. Since mice do not produce fetal hemoglobin as seen in humans, the
human embryonic ε-globin gene is expressed in the cells derived from the yolk sac. Fetal γglobin genes and the adult β- and δ-globin genes are expressed in the cells derived from the fetal
liver and bone marrow, respectively. A method for how to overcome this major drawback to
performing in vivo studies on βYAC transgenic mice is yet to be discovered.
A naturally occurring mutation in mice called neonatal anemia (Nan) is a semi-dominant
hemolytic anemic phenotype present on chromosome 8 first described in 1985 (Lyon MF, 1986).
At E11 Nan homozygotes die due to lack of hematopoiesis. To further study this mutation Nan
mutant models were created to pinpoint the location of the mutation which was determined to be
a single amino acid change E339D within the second zinc finger of KLF1 (Siatecka et al., 2010).
The first KLF1-/- knockout mouse models were created in 1995 by either inserting a) the
neomycin antibiotic resistance gene into the second of three exons of KLF1 to disrupt the zinc
finger binding domain (Perkins AC et al., 1995) or b) a LacZ reporter gene and neomycin
antibiotic resistance gene cassette in the ATG codon, which would prevent initiation of
translation of KLF1 protein (Nuez et al., 1995). This study is using the KLF1 knockout mouse
model developed by Perkins AC et al. in 1995. Only through the construction of these knockout
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mice have researchers been able to discover what role KLF1 plays in the body as previously
discussed in section 1.4.1.

1.7 Rationale
The β-hemoglobinopathies, sickle cell disease and β-thalassemia, are major sources of
morbidity and mortality worldwide. Understanding the underlying mechanisms involved in the
switch from fetal to adult hemoglobin and reactivation of γ-globin gene expression in adults is
vital in discovering a cure for these diseases.
Based on previous research, multiple sometimes seemingly contradictory roles for KLF1 in
-globin gene regulation have been put forth. KLF1 directly upregulates (Alhashem et al., 2011;
Perkins AC et al., 1995; Perkins AC et al., 1996; Wijgerde et al., 1996), indirectly downregulates
(Perkins AC et al., 1995; Funnell et al., 2013; Nuez B et al., 1995; Zhou D et al., 2010) or
directly downregulates (Miller IJ et al., 1993; Pilon AM et al., 2008) γ-globin gene expression.
Elucidating the positive and negative roles of KLF1 in regulating γ-globin gene expression as a
first step, will help in clarifying this ongoing debate. This will be done by examining five γ globin gene repressors LSD-1, LRF, c-MYB and the NuRD complex genes Mi2β and MBD2. As
discussed in section 1.5, knockdown of c-MYB (Ramsay RG et al., 2008), LSD1 (Xu J et al.,
2013), BCL11A (Bauer et al., 2012; Leid M et al., 2004; Kuo TY et al., 2010; John A et al.,
2012) and Mi2-β (Larsen DH et al., 2010) with the end goal of increasing HbF has been shown
to adversely affect processes other than erythropoiesis. LSD-1 has a minor role in repressing γglobin and is therefore alone is not an efficient target of therapy. Testing knockdowns of KLF1,
which is expressed in erythroid cells, will only affect processes involved in erythropoiesis and
have less chance of unwarranted adverse effects. Utilizing the ~40-70% knockdown of KLF1
38

which has no known adverse effects on model organisms would help us understand the
comprehensive role it plays in regulating γ-globin gene expression via these repressors. For
example, a patient with sickle cell disease had ameliorated symptoms and 20.3% HbF, due to a
heterozygous mutation that resulted in the genotype: c[914-1_914-4 del CTAG] that deleted 4
base pairs of one of his KLF1 genes (Gallienne AE et., 2012).
The intent of this research is to decode the indirect mechanism of action of KLF1on γ-globin
repression. Therefore, ~40% to 70% knockdown of KLF1 will be utilized while performing
experiments in mice and HUDEP-2 cells on the five prominent repressors genes of γ-globin gene
expression: CHD4/Mi2β, LRF/ZBTB7A, LSD1/KDM1A, MBD2 and c-MYB. It will be of
interest to look at the role of KLF1 in regulating these γ-globin gene repressors and to study the
evolutionary conservation of this mechanism between mice and humans for more insight into the
regulation of hemoglobin switching.
Therefore, we hypothesize that KLF1 actively regulates transcription of some of these
repressors by directly binding to their promoter regions in both mouse fetal livers and the human
HUDEP-2 cell line.
It was previously shown that γ-globin mRNA levels were significantly elevated with ~4070% knockdown of KLF1 when compared to the control. But, the γ-globin mRNA levels were
not significantly increased or decreased with >80% knockdown of KLF1 when compared to the
control. This phenomenon is termed the threshold amount of KLF1, i.e. a certain amount of
KLF1 is required by cells to produce γ-globin levels significantly greater than normal. We also
hypothesize that the KLF1 knockdowns will result in the same relative amounts of γ- and βglobin protein as that of mRNA.
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Figure 1.8: Regulation of β-Globin Expression by KLF1 in Erythroid Cells Derived
from Human Umbilical Cord Blood CD34+ Hematopoietic Progenitors Follows a Linear
Pattern
There is a positive correlation observed between the amount of KLF1 mRNA present on the Y-axis
and the corresponding amount of β-globin expression by linear regression analysis. Adapted from
Vinjamur DS, 2016, PLoS ONE.
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Figure 1.9: Regulation of γ-globin Expression by KLF1 in Erythroid Cells Derived from
Human Umbilical Cord Blood CD34+ Hematopoietic Progenitors Follows a Non-Linear
Pattern.
A) No correlation was observed between the amount of KLF1 mRNA present in cells and the
corresponding amount of γ-globin expression by linear regression analysis. A non-linear model made
the smooth curve shown in the figure. B) A statistically significant increase in γ-globin mRNA levels
was observed when compared to control. Adapted from Vinjamur DS, 2016, PLoS ONE.
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Chapter 2: Materials and Methods

2.1 Studies in the Mouse and HUDEP-2 Cell Line

2.1.1 Generation of mouse models
The KLF1 knockout (KO) mouse model was generated by targeted insertion of the neomycin
resistance gene (Figure 2.1) (Perkins, Sharpe, Orkin 1995; Vinjamur DS, 2014).

2.1.2 Mouse Dissection and Collection of Fetal Livers
For the qRT-PCR, non-transgenic wildtype mice were bred with KLF1+/- mice to obtain
KLF1 +/+ or KLF1 +/- offspring. For ChIP assays, non-transgenic wildtype mice were bred with
each other to obtain KLF1 +/+ offspring. The fetal liver, brain and placenta were collected from
each fetus at E12.5 and E14.5 as described (Alhashem et al., 2011). Females in the timed mating
were checked every morning for the presence of a vaginal plug, indicating a successful mating,
after which the plugged females were separated from the males and that day was considered
E0.5. At E12.5 or E14.5 for qRT-PCR or ChIP assays respectively plugged females were
dissected after being anesthetized using isofluorine, followed by cervical dislocation. The uterine
horns were dissected out and whole mouse fetuses were placed in Petri dishes containing 1X
PBS to prevent dehydration of the fetuses and contamination with maternal tissue. One fetus was
processed at a time by separating maternal tissue from the yolk sac and care was taken to ensure
that the yolk sac with the fetus inside did not rupture and lose blood. To collect fetal liver, E12.5
or E14.5 fetus is dissected out of their yolk sac before fetal liver is dissected away from other
embryonic tissues. The fetal liver was then transferred into a clean well filled with 1X PBS and
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rinsed thoroughly before being stored in a vial in liquid nitrogen. The dissected brain and
placenta of each mouse fetus was stored at 4°C.

2.1.3 Genotyping
The ear punches obtained from by ear-punching the mice at 3-4 weeks of age was used to
genotype adult mice. The fetal brain or placenta collected during dissection as mentioned in
section 2.1.2 were used to genotype E12.5 and E14.5 fetuses. These tissues were digested
overnight in a water bath at 55-60°C in 50 μl digestion buffer for ear punches and 500 µl
digestion buffer for the fetal brain or placenta (10 mM Tris HCL, pH 8.5; 50 mM KCl, 40 mM
MgCl2, 0.45% Tween 20 and 0.45% NP40) containing 1μg/μl proteinase K (Roche, PCR grade).
The following morning after digestion, proteinase K was inactivated by 2 cycles of alternate
boiling (> 95°C) and cooling (4°C) for ten minutes each. A Polymerase Chain Reaction (PCR)
was performed using genotyping primers designed by Yousef Alhashem (Alhashem Y et al.,
2011) seen in (Table 2.1) and 2 - 5 μl of the resulting tissue lysate was run on a 2% agarose gel at
100 V for 45 minutes to one hour. A 100 bp ladder was run along with the samples. The wildtype
mice have one band that is 170 bp and the KLF1 +/- mice have two bands one of 170 bp and one
of 220 bp for each allele.

2.1.4 RNA extraction and cDNA synthesis
After genotyping was performed, the mouse fetal livers collected at E12.5 and stored in
liquid nitrogen were removed and resuspended in 400 μl denaturation solution (Totally RNA
total RNA isolation kit, Ambion) and thawed on ice. 1/10th volume of the denaturation solution
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of 3M sodium acetate (Totally RNA kit, Ambion) was added, followed by 400μl of acid-phenol:
chloroform (pH 4.5, Totally RNA 42 kit, Ambion). The samples were inverted and then

Figure 2.1: Graphical Representation of Knockout and wildtype KLF1 Alleles
Insertion of neomycin resistance gene to form the knockout allele

Table 2.1: Mouse KLF1 Genotyping Primers
Gene & Allele

Primer

KLF1 KO

Forward Primer GCCAGAGGCCACTTGTGTAG
Reverse Primer

KLF1 WT

Primer Sequence 5’ to 3’

220

CTGGGACCTCTGTCAGTTGC

Forward Primer GGTGAACCCGAAAGGTACAA
Reverse Primer

Amplicon Length

CTGGGACCTCTGTCAGTTGC
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vortexed for one minute and then centrifuged at 12,000 X g for 10 minutes at 4°C. After
centrifugation, the aqueous phase was transferred to a fresh 1.5 ml tube again 400 μl of acidphenol: chloroform (pH 4.5, Totally RNA 42 kit, Ambion) was added to each tube. The samples
were inverted and then vortexed for one minute and then centrifuged at 12,000 X g for 10
minutes at 4°C. After centrifugation, the aqueous phase was transferred to a fresh 1.5ml tube and
4 μl of glycogen (5mg/ml stock, Ambion) and an equal volume of cold 100% isopropanol was
added to the sample and mixed by inverting the tubes 4-5 times. RNA was allowed to precipitate
overnight at -80°C. The following day, samples were thawed on ice and centrifuged at 12,000 X
g for 30 minutes at 4°C. The supernatant was discarded and the pellet was washed with 1 ml of
chilled 80% ethanol. The ethanol was discarded and the pellet was air-dried for 2-5 minutes on
ice. The pellet was then resuspended in 20 μl of RNase-free water (USB Corporation) containing
SuperaseIn (1:20 dilution, Ambion). 2 μl of the resuspended pellet was run on a 1% agarose gel
to determine if the 28S and 18S rRNA subunits are intact to assess the quality of total RNA
purified. The concentration of the remaining 16 µl of RNA of each mouse fetal liver sample was
tested using a NanoDrop (Thermo Scientific NanoDrop 3300). Based on these concentrations the
samples were further diluted to determine RNA integrity and concentration using the Agilent
Bioanalyzer and the Agilent RNA 6000 Pico kit (Agilent Technologies), following the
manufacturers protocol. For each fetal liver sample, a total of 1 μg of RNA was treated with
DNaseI (Life Technologies) and used to prepare cDNA in 20 µl of solution following the
instructions of the iScript cDNA synthesis kit (BioRad) to give a stock cDNA concentration 50
ng/µl.
For RNA preparations from the human HUDEP-2 samples, the cells were spun down
after three days of differentiation and every ~2-3 x 106 cells were resuspended in 750 µl TRIzol
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reagent (Thermofisher Scientific) and incubated for 5 minutes. 200 µl of chloroform was added
and cells again incubated for 3 minutes and then centrifuged at 12,000 rpm at 4°C for 15
minutes. The aqueous phase was transferred to a new tube and 5 µl of glycogen and 500 µl
chilled isopropanol were added to each sample and then incubated for 10 minutes on ice after
which the tubes were stores at -80ºC overnight. After incubation samples were centrifuged for 15
minutes at 4°C at 12,000 rpm. The supernatant was discarded and the pellet was washed with 1
ml of chilled 80% ethanol. The ethanol was discarded and the pellet was air-dried for 2-5
minutes on ice. The pellet was then resuspended in 20 μl of RNase-free water (USB Corporation)
containing SuperaseIn (1:20 dilution, Ambion).

2.1.5 Primer Design
The primer pairs were designed for qRT-PCR utilizing SYBR green reagent. The most recent
human or mouse genome was selected in the UCSC Genome and then an exon common to all
transcripts of the gene of interest was selected to design the primer around. Then the link of the
RefSeq number from the UCSC genome to NCBI database was followed. The FASTA sequence
was opened and that particular exon was picked out and 400 bases were copied into the
Integrated DNA Technologies (iDT) design a primer program (200 bases before and 200 bases
after the exon start). The primer pair where one of the primers extended the exon-exon junction
was selected and BLAST was run to ensure specificity of the pair. It should be noted that two
primer pairs were designed for each gene and tested afterward on qRT-PCR as amplicon sizes <
100 bp and so running an agarose gel was not feasible. The primer pair with higher efficiency,
i.e., lower Ct value with amplification of one product, was selected.
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The Primer pairs utilized in the ChIP assay qPCR experiments were designed differently.
Those genes which showed a statistically significant difference in expression between the WT
and KLF +/- mice and the HUDEP-2 scramble and K1V1 or K1V2 samples had primers
designed around the CACCC regions present in the promoter regions of the genes, i.e., the
promoter regions of the genes from -600 base pairs of the transcription start site (TSS) to the
TSS, designated as 0, were downloaded using Ensembl. Then CACCC and complementary
regions were identified and listed in order of which site was most similar to the designated 10
base pair consensus sequence (Tallack et al., 2011). Then the primers were designed around
these sites using the same software as above, however the only difference was the primers were
designed such that the CACCC sites were found in the middle of the amplicon (or as close to the
middle as possible). This was to ensure that after sonication a maximum number of chromatin
fragments held the protein.

2.1.6 Quantitative reverse transcriptase PCR (qRT-PCR)
Standard curves were made by serially diluting the 50 ng/µl stock cDNA to 25 ng/µl. Then
serial dilutions in 1:5 ratio were obtained, i.e., 25 ng/µl to 5 ng/µl to 1 ng/µl to 0.2 ng/µl and to
0.04 ng/µl. Since Cyclophilin A is an abundant mRNA only 1 ng of each cDNA sample was
loaded into each well whereas for mRNAs that are less abundant such as MBD2, 5 ng of cDNA
were loaded into each well. Using the standard curves, known quantities of cDNA were used to
perform absolute quantification (AQ) of the samples to determine mRNA amounts. A qRT-PCR
was carried out using the SYBR Green reagent (Applied Biosystems) and plates were run on an
ABI Prism 7900HT Fast Real-Time PCR System (Applied Biosystems). The various quality
control measures applied to all results were: The R-value of the standard curve must be > 0.95,
the amount of cDNA in all samples must fall within the limits of the standard curve, each sample
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was run in quadruplet, at least three out of the four readings obtained for each sample must be
within 20% of the mean quantity for all four readings. That is between 80% and 120% of the
quantity mean, otherwise that reading was discarded and not used for further analysis.
Cyclophilin A mRNA was used as the internal standard for normalization. Primer sequences
used for qRT-PCR analyses of the mouse and human genes are listed in Table 2.2.
Three female mice were dissected to obtain 8 E12.5 KLF1 +/- and 8 E12.5 KLF1 +/+ fetuses
which were compared to each other. The primer efficiency was calculated for each primer set
and then the average Ct value for each sample of both the test gene and Cyclophilin A were
calculated using: original Ct + Log(Primer efficiency, ng of sample added in each well). Next,
the number of copies of Cyclophilin A and the test gene were calculated for each sample using
the formula: Primer Efficiency^ (-1*Corrected Ct). To get the final fold change of the test gene
normalized to Cyclophilin A the number of copies of test gene was divided by the number of
copies of Cyclophilin A. An X by Y analysis was done in JMP and the mean of KLF1 +/+ vs.
KLF1 +/- obtained from JMP was plotted in the bar graphs seen in the results section.
Ten knockdown samples (five K1V1 and five K1V2) were compared to five scramble control
samples in the human HUDEP-2 cell line. The data analysis was similar to mice; primer
efficiency, copy number and fold change were calculated using the same formulas. Additionally,
the expression of each gene was set to 100 for scramble-treated cells and fold change over
scramble was calculated for KLF1-shRNA infected cells, to minimize variations observed due to
differences between each HUDEP-2 sample.
The cDNA was obtained and serially diluted similar to how the mouse samples were
prepared. Absolute quantification (AQ) of the samples performed quantitative reverse
transcriptase PCR (qRT-PCR) to analyze changes in gene expression in knockdown samples
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(K1V1 and K1V2) compared to scramble controls. Additionally, the expression of each gene was
set to 100 for scramble-treated cells and fold change over scramble was calculated for KLF1shRNA infected cells, to minimize variations observed due to differences between each HUDEP2 sample. The same quality control measures as in mice were also applied here.

Table 2.2: Human and Mouse qRT-PCR Primer Sequences
Gene

Primer Sequence 5’ to 3’

Primer Length

Product Size

110

mLRF
Forward Primer

CTGTAAAGTTCGATTCACCAGAC

23

Reverse Primer

CACTGCTGGCACAGGTA

17

Forward Primer

GAAGAGCCGTCTGGTGTG

18

Reverse Primer

CTGCTTCCTGAGAGGTCATTC

21

Forward Primer

GAAGGAGGAAGTGATCCGAAA

21

Reverse Primer

CTTCTTACCACTTGGACTGAAGTA

24

Forward Primer

TCCATCTCAGCTCTCTCCAA

20

Reverse Primer

GGAACGTGACTGGAGATGTTT

21

Forward Primer

CAGTGAGGAGGAGGATATGGA

21

Reverse Primer

GATAAATCCTCGTCTGGGTCTTC

23

mLSD1
102

mMBD2
69

mc-MYB
134

mMi2-β

mCyclophilin A

49

127

Forward Primer

ATTTCTTTTGACTTGCGGGC

20

Reverse Primer

AGACTTGAAGGGGAATG

17

Forward Primer

TGCAAGGTCCGCTTCAC

17

Reverse Primer

TCGTAGTTGTGGGCAAAGG

19

Forward Primer

CTGACATTTGAGGCTACTCTCC

22

Reverse Primer

AGATGCCGAAGTTGATAAGACC

22

Forward Primer

CAGAGACGTGGCAAGAGGG

19

Reverse Primer

GTTTCTCCGAGGGCAAGAGG

20

Forward Primer

GATGGGCAGAAATCGCAAAG

20

Reverse Primer

TGCAGATAACCTTCCTGTTCG

21

Forward Primer

ATAAAGATAAGCCATTGCCTCC

22

Reverse Primer

GACATATGCCTTGAACTCTTTCTC

24

Forward Primer

CCGAGGAAAACCGTGTACTATTAG

24

Reverse Primer

TGCTGTCTTTGGGACCTTG

19

GCAAGGTGAACGTGGATGAAGT

22

112

hLRF
74

hLSD1
78

hMBD2
97

hc-MYB
122

hMi2-β
101

hCyclophilin A
103

hβ-globin
Forward Primer

50

97

Reverse Primer

TAACAGCATCAGGAGTGGACAGA

23

Probe

CAGGCTGCTGGTGTACCCTTGGACCC

26

Forward Primer

GTGGAAGATGCTGGAGGAGAAA

22

Reverse Primer

TGCCATGTGCCTTGACTTTG

20

Probe

AGGCTCCTGGTTGCTACCCATGGACC

26

Forward Primer

GCAAGAGCTACACCAAGAG

19

Reverse Primer

GTGTTTCCGGTAGTGGC

17

hγ-globin
81

hKLF1
96

2.1.7 Chromatin Immunoprecipitation (ChIP)
ChIP assays were performed as previously described (Hou et al., 2008). 1% formaldehyde
was added to each biological replicate of ~5 x 106 blood cells to cross-link for 10 minutes at
room temperature. In mice three E12.5 fetal livers were mixed to obtain one sample and in the
human HUDEP-2 cell line ~10 x 106 cells were used for one sample. A total of three samples
were used for ChIP assays in both mice and human models. Then, 125 mM glycine was added to
inhibit crosslinking and replicates were incubated at room temperature for 5 minutes. The cells
were centrifuged at 300 X g for 5 minutes and the supernatant was discarded. Cell lysis buffer
(10 mM Tris, 10 mM NaCl, 0.2 % NP-40 [pH 8.0], and three protease inhibitors – Pepstatin,
AEBSF and Aprotinin) was then added to lyse the cells and was then centrifuged at 500 X g for
5 minutes. To release the chromatin, the nuclei which is present as a pellet, is lysed with 0.5 ml
Nuclei lysis buffer (50 mM Tris, 10 mM EDTA, 1% SDS, and three protease inhibitors) for 10
minutes on ice. 100 µl of IP dilution buffer (20 mM Tris, 150 mM NaCl, 2 mM EDTA, 0.01%
SDS, 1% Triton X-100, and three protease inhibitors) is added for every 2 x 106 cells and
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distributed to 300 µl per 1.5 ml tube. A bioruptor sonicator (Diagenode, Sparta, NJ) was utilized
to shear the chromatin using the following settings: 3 cycles of: “H” level, 30 sec ON, 30 sec
OFF, for 10 min (Total time 30 mins, 15 mins sonication time). While sonicating the chromatin,
the Protein G Agarose (Millipore, Cat. 16-266) was washed three times using IP dilution buffer
then kept at 50 µl per IP in the same buffer. After sonification ~10 µl of the chromatin was run
on a 1% agarose gel to look at the size of the sheared chromatin fragments. The sheared
chromatin was then centrifuged for 10 minutes at 10,000 X g at 4°C. The supernatant which
contains the soluble chromatin is moved to a new tube and diluted to 1 ml per antibody using the
IP dilution buffer. 10% of the chromatin is aliquoted into a new tube and stored at -20°C for the
input DNA. Chromatin is distributed to one tube per antibody with 1 ml chromatin per tube. 5 µg
of each antibody is added to the chromatin and 50 µl of washed protein G agarose is added to
each tube which is incubated at 4°C overnight. The following day, the sheared chromatin is
washed twice with 500 µl of IP wash buffer 1 (20 mM Tris, 50 mM NaCl, 2 mM EDTA, 0.1%
SDS, 1% Triton X-100 [pH 8.1]), once with IP wash buffer 2 (10 mM Tris, 0.25 M LiCl, 1 mM
EDTA, 1% Nonidet P-40, 1% Desoxycholate [pH 8.1]) and twice with TE (pH 8.0). 400 µl
freshly prepared IP elution buffer (0.1 M NaHCO3, 1% SDS (10ml: 1M NaHCO3 1ml, 20%
SDS 0.5ml, water 8.5 ml) is added to each tube to elute the chromatin. Eluted chromatin is
centrifuged to remove the agarose beads and is incubated at 65°C for 6 hours after adding NaCl
(final concentration 0.3 M) and proteinase K (0.25 mg/ml). The proteinase K is deactivated by
incubating the chromatin at 95°C for 10 minutes. An extraction with phenol chloroform is
performed. Purified DNA is quantitated using quantitative PCR (qPCR) and SYBR Green
chemistry. Fold enrichment was calculated as 2^ (Ct.input – Ct.test) and expressed relative to the
IgG control. Antibodies used for mouse-ChIP: Anti-KLF1 (Abcam, ab2483); non-specific Rabbit
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IgG (Abcam, ab46540). Antibodies used for human-ChIP: Anti-KLF1 (Abcam, ab2483); AntiHuman IgG (Abcam, ab2410). Primer sequences used for qPCR analyses of the mouse and
human HUDEP-2 ChIP assay genes are listed in Table 2.3.

Table 2.3: Mouse and Human qPCR Primer Sequences for ChIP Assays
Primer Sequence 5’ to 3’

Primer Length

Product Size

Forward Primer

TAGCCTCGAACTCACAGAGA

20

95

Reverse Primer

CCCGCATTTACCAACACATTT

21

Forward Primer

CCAGGCGCTGGTTCTAACTCCAGGC

20

Reverse Primer

GCTGGCCACCAGACGACCTGACTGT

20

Forward Primer

CCCTGTCTCAATTAGGTAGTAAGC

24

Reverse Primer

CACTTCAACTAATAACATTCACTCTCC

27

Forward Primer

CCTGCAGGGAGAGTGAATGTTAT

23

Reverse Primer

GCCTGACTTCGGGTTCTGA

19

Forward Primer

GCTTCTGACATAGTTGTGTTGACTCA

26

Reverse Primer

CAGCAGCCTTCTCAGCATCA

20

ACCCCATTGAACATGGCATT

20

Gene
mLRF-1 ChIP

mLRF-2 ChIP
106

mLSD1-1 ChIP
135

mLSD1-2 ChIP
87

mβmaj-promoter ChIP
104

mβActin ChIP
Forward Primer

53

73

Reverse Primer

TGTAGAAGGTGTGGTGCCAGAT

22

Forward Primer

ACTGAGGCCCGGGGAG

16

Reverse Primer

CACAGCGAGGAGCGAC

16

Forward Primer

GTCGCTCCTCGCTGTGC

17

Reverse Primer

TAAACAGGCCCCCAGCCT

18

Forward Primer

CAGAGACGTGGCAAGAGGG

19

Reverse Primer

GTTTCTCCGAGGGCAAGAGG

20

Forward Primer

GCTAGAACTTCATAATGTAACCCTTG

26

Reverse Primer

CCATTTCCTCCAGGGACTTT

20

Forward Primer

CGAGAACGTCCGCTCTATGG

20

Reverse Primer

AGGGACAAAAAGGGTCGGAG

20

Forward Primer

GGACACTTTGCTTCATTCCTTC

22

Reverse Primer

ACATACCAACTCGGCTATTCAT

22

Forward Primer

CTAACCACAGTCACTATGACACC

23

Reverse Primer

CATCTTGTCTCCGCCTTCTC

20

hLRF-1 ChIP
141

hLRF-2 ChIP
99

hLRF-3 ChIP
115

hLSD1-1 ChIP
83

hLSD1-2 ChIP
80

hMBD2-1 ChIP
111

hMBD2-2 ChIP

hc-MYB1 ChIP

54

119

Forward Primer

CCAGAGGGCACAGTTGTAAA

20

Reverse Primer

GGACCAGAGCTCCTCCA

17

Forward Primer

GGTTTGCTCAGGAAAAGGCG

20

Reverse Primer

CGCGGTGCGCCTAGC

15

Forward Primer

CAAATATCTGTCTGAAACGGTCCCT

24

Reverse Primer

TGCCTTGTCAAGGCTATTGGT

21

Forward Primer

GAGGGTTTGAAGTCCAACTCCTAA

24

Reverse Primer

CAGGGTGAGGTCTAAGTGATGACA

24

Forward Primer

TTCGTCCAGCAGAATTACCTGAAG

24

Reverse Primer

GGACCCCCAGAAGAACTCGTA

21

126

hc-MYB2 ChIP
144

hγ-promoter ChIP
86

hβ-promoter ChIP
116

hNecdin ChIP
134

2.1.8 Statistical Analysis
The Student’s one-sample, one-tailed t-test was used for statistical analyses. P values < 0.05
for qPCR and P values < 0.025 for qRT-PCR and western blot were considered significant.

2.2 Studies in the Human-Umbilical Cord Blood Derived Erythroid Progenitor (HUDEP2) Cell Line
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2.2.1 Expansion of HUDEP-2 Cell Line
The HUDEP-2 cells were obtained from Dr. Yukio Nakamura (RIKEN Bio Resource
Center, Tsukuba, Ibaraki, Japan). They were established by immortalization of umbilical cord
blood CD34+ cells using lentiviral delivery of a Tet-inducible HPV16-E6/E7 transgene
(Nakamura Y et al., 2013). The human papillomavirus 16 (HPV16) E6 and E7 proteins induce
immortalization of cells by inhibiting the function of the p53 and retinoblastoma (pRb) tumor
suppressor proteins respectively (Münger K, Howley PM, 2002). The HUDEP-2 cells most
closely resemble adult erythroid cells since they express predominantly β-globin upon culture in
erythroid differentiation media, whereas the HUDEP-1 and HUDEP-3 lines express
predominantly γ-globin. Additionally the HUDEP-2 (but not HUDEP-1 or HUDEP-3) line
expresses BCL11A, a known repressor of γ-globin.
HUDEP-2 cells were stored at 1-2 x 106 cells/ml at -196°C in FBS with 10% DMSO in
cryovials. To begin expansion one vial of HUDEP-2 cells is removed from liquid nitrogen and
warmed at 37°C until thawed. Contents of the vial are added to a conical 15 ml tube with 14 ml
of Serum-Free Expansion Medium (SFEM). The tube is centrifuged at 300 rcf for 3 minutes and
the pellet is then dissolved in 1 ml of HUDEP-2 expansion medium and placed in one T25 flask
containing 5 ml of expansion medium. The HUDEP-2 cells are then grown in expansion medium
for 10 days in T25 flasks at a cell density of 1-2 million cells/ml. Pelleted HUDEP-2 cells are a
light pink in color after 10 days in expansion medium. Cells were counted and medium changed
every 2-3 days. Expansion medium: SFEM medium (Stem Cell Technologies) containing 2%
penicillin/streptomycin (Gibco), 1 µg/ml doxycycline (BioBasic), 1 x 10-6 M dexamethasone
(Sigma-Aldrich), 3 U/ml erythropoietin (Amgen) and 50 ng/ml human stem cell factor (Stem
Cell Technologies). Doxycycline inhibits differentiation of the HUDEP-2 cells as it is used as a
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substitute for Tet, and the presence of doxycycline induces HPV16-E6/E7 expression.
(Nakamura Y et al., 2013).

2.2.2 Calcium phosphate transfection of 293T Cell Line
293T stock cells were stored at -196°C in FBS with 10% DMSO in cryovials. To begin
transfection one vial of 293T cells are removed from liquid nitrogen and warmed at 37ºC until
thawed. Contents of the vial are added to a conical 15 ml tube with 14 ml of Dulbecco’s
modified Eagle’s medium-complete (DMEM with 10% FBS and 1% Penicillin/Streptomycin).
The tube is centrifuged at 300 rcf for 3 minutes and the pellet is then dissolved in 1 ml of
DMEM-complete and placed in one T75 flask containing 14 ml DMEM-complete. The 293T
cells were transferred to round tissue culture plates at ~5 million cells per plate. The 293T cells
were divided evenly into three categories for the calcium phosphate transfection: mock,
scramble, K1V1 (~40-70% KD) and K1V2 (>75% KD). Lentiviral vectors carrying KLF1targeted shRNA coding sequences were acquired from other labs. Two KLF1-targeted shRNA
vectors (pRRL K1V1 and pRRL K1V2) and a scrambled shRNA vector (pRRL Scramble) were
acquired from Dr. François Morlé (Université Claude Bernard Lyon1, Lyon, France) and Dr.
Fawzia Louache (INSERM, Villejuif, France). These vectors were constructed on a pRRL
backbone (Bouilloux, Blood 2008) with the shRNA-coding sequence under the control of the H1
promoter and also carry a GFP-coding sequence. The oligonucleotide sequences are listed in
Table 2.3. Bacterial culture with plasmid was plated on LB agar plates containing 100μg / ml
Ampicillin (Thermo Fisher Scientific). One ampicillin resistant colony of each plasmid was
picked from each transformation reaction and cultured for mini preps (VCU Molecular Biology
Core). The lentivirus is produced when the packaging plasmid pCMV-dR8.74, the envelope
plasmid pMD2G and one of the three pRRL plasmids (K1V1, K1V2 or scramble) are co57

transfected into 293T cells (semi-confluent in 10 cm tissue culture dishes). The packaging and
envelope plasmids were a gift from Dr. Gordon Ginder’s laboratory. After being grown in a
culture dish for 24 hours, the 293T cells were transfected. The transfection solution was prepared
separately in a single 5 ml falcon tube for each of the categories, mock, scramble and
knockdown. Each tube had 1 ml and is used to transfect one round tissue culture dish. For all
categories, we combined 5.6 µg of pCMVRd8.74 and 2.3 µg of pMD2.G and sterile water up to
437 µl in the falcon tube. The tube was tilted to add 63 µl of 2 M CaCl2 down the side of the
tube. Next, 500 µl HBS Solution was added in the same manner to make a total volume of 1 ml.
For scramble, 7.5 µg of pRRL encoding scramble shRNA was additionally added. For K1V1 and
K1V2 knockdown, 7.5 µg of pRRL-pK1V1 or pRRL-K1V2 was additionally added respectively.
The 1 ml of transfection solution was added dropwise to the respective 293T plate. Starting from
the center of the plate and continuing in a spiral pattern of approximately 6 concentric circles
towards the edge of the plate, distributing the drops evenly. Each plate was incubated at room
temperature for 5 minutes. The plates were grown for 16-18 hours in a 37°C incubator at 3%
CO2. After 18 hours the cells begin to die due to CaPO4 formation, which disrupts the cell
membrane. So, the medium was removed and 15 ml of DMEM with 2% FBS and 1%
penicillin/streptomycin warmed to 37ºC was added to each plate then incubated at 37°C, 10%
CO2 overnight. The following day, the medium containing viral particles was collected and first
filtered through a 0.45μm filter, supplemented with polybrene, making the lentivirus ready for
infection of HUDEP-2 cells.
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2.2.3 Lentiviral infection of HUDEP-2 Cell Line
The HUDEP-2 cells were then collected, spun down and resuspended in HUDEP-2
expansion medium at ~5 x 106 cells/ml. 800 μl to 1 ml of lentiviral medium is added to 2 x 105
HUDEP-2 cells in 100 μl expansion medium in each well of a 12 well tissue culture plate and are
incubated at 37°C at 5% CO2. The following afternoon, the cells were collected and spun down
to remove the viral medium. The infected HUDEP-2cells are then resuspended in 650μl of
expansion medium and returned to the incubator for another two days.

2.2.4 Differentiation of HUDEP-2 Cell Line
Three days after infection the HUDEP-2 cells are resuspended in differentiation medium.
differentiation medium: IMDM medium (Sigma-Aldrich) with 2% penicillin/streptomycin
(Gibco), 1µg/ml doxycycline (BioBasic), 3 U/ml erythropoietin (Amgen) and 50 ng/ml human
stem cell factor (Stem Cell Technologies), 5% human serum albumin (Thermo Fisher Scientific),
500 µg/ml human holo-transferrin (Gemini), 1% L-glutamine (Thermo Fisher Scientific), 10
µg/ml human insulin (Gemini) and 3 U/ml heparin (Gemini). The infected HUDEP-2 cells are
differentiated for three days (DD3) for qRT-PCR, ChIP assays and for protein analysis. The
pelleted cells appear red after three days of differentiation.

2.2.5 Western Blot
Protein extraction began by spinning down one HUDEP-2 sample of ~1 x 106 cells after 3
days of differentiation. The number of samples tested for β-globin protein detection was three
K1V1, three K1V2 and four Scramble controls. The number of samples tested for γ-globin
protein detection was three K1V1, three K1V2 and three Scramble controls. The cells were then
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resuspended in 1 ml PBS and transferred to a 1.7 ml micro centrifuge tube and again spun down
and resuspended in PBS then centrifuged at 18,000 X g for 1 minute and all PBS was removed.
Every 1 x 106 cells were resuspended in 100 µl of RIPA buffer (1 M Tris-HCl, 0.5 M EDTA,
5M NaCl, 20% glycerol and NP-40) containing 2 µl of 50X protease inhibitor cocktail
(Promega). The cells were then incubated in this buffer on ice for 45 minutes and then
centrifuged at 18,000 X g for 15 minutes at 4°C. The supernatant contains the isolated protein
and was collected and moved to a new micro centrifuge tube and kept on ice. To calculate the
concentration of protein we took the absorbance readings of 6 standards containing 1 ml BioRad
protein reagent with no bovine serum albumin (BSA), 2µl, 4 µl, 8 µl, 16 µl or 32 µl of BSA
using a spectrophotometer. Using these values a standard curve was plotted for calculation of
protein concentrations of the samples. The test samples were set up and contained a mixture of 1
ml protein reagent and 2 µl protein sample. After obtaining the protein concentrations of the
samples from this standard curve we correct the value for the 5 X Laemmli buffer that was later
used in SDS-polyacrylamide gel (SDS-PAGE) and for the 2 µl of protein added: Final protein
concentration = (protein concentration x 0.8)/2.
After analyzing the protein concentration each sample’s protein was diluted so as to load
30 µg of protein per well in a 10 cm x 8 cm x 5 mm gel. This was done by preparing the 30 µg in
4 µl of sample with 10 µl of Laemmli buffer and heating in a water bath at 95°C for 5 minutes
and then spun down and loaded on the 8% SDS-PAGE. The resolving gel components were 40%
acrylamide, 10% APS, 10% SDS, TEMED and 1.5 M Tris pH 8.8. The stacking gel components
were 40% acrylamide, 10% APS, 10% SDS, TEMED and 0.5 M Tris pH 6.8. After loading the
wells of the gel with the samples and the pre-stained low molecular weight range protein ladder,
(Thermo Fisher) the gel was run for the first 30 minutes at 70 V and later at 100 V until the
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loading dye reached the end of the gel. After this the gel was removed and placed in transfer
buffer (10% SDS, methanol, Tris Base, Glycine) for one hour on a rotator. The molecular
weights of β-Actin, β-globin and γ-globin are 42 kDa, 16 kDa and18 kDa respectively.
The transfer sandwich was made by placing these things in order from the black side of
the cassette: a wet sponge, wet blot paper, the gel from above, nitrocellulose membrane, blot
paper and sponge (white side of cassette), at each stage the bubbles were removed with a roller.
The cassette was closed and placed in the holder with an ice pack and run at 100 V for 90
minutes. After transfer, the nitrocellulose membrane was removed and rinsed in PBS-T (PBS
with 0.05% Tween-20) and subsequently stained with Ponceau Red stain for 10 seconds on a
rocker to check that transfer occurred, here the membrane was cut above the 60 kDa mark on the
ladder to conserve antibodies. To remove the stain, the membrane was again washed with PBS-T
and then incubated for 30 minutes on a rocker with 5% dry milk solution as a blocking solution.
After blocking the membrane, PBS-T was used to rinse once again. The membrane was
incubated in 1X TBS, 0.1% Tween-20, 1% BSA, 1% calf serum dilution with a 1:1000 dilution
of either the γ-globin (sc-21756) or β-globin (sc-21757) primary antibody overnight at 4°C on a
rotating shaker. The following morning, the membrane was washed with PBS-T and then 1-2 ml
of chemiluminescence (ECL) was uniformly pipetted over the membrane and observed in the
dark room. The membrane was then washed with PBS-T after viewing and immersed in stripping
buffer on the rocker for 15 minutes. The stripping buffer was removed and blocking agent was
added. The control antibody β-Actin (C4) (sc-47778) was then added at a 1:1000 dilution in 1X
TBS, 0.1% Tween-20, 1% BSA, 1% calf serum dilution overnight at 4°C to the membrane and
the process was repeated to view the control bands on the membrane.
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The relative densities of each sample were calculated using ImageJ. Each of the sample
bands was normalized to β-actin bands of the 16 kDa β-globin and 18 kDa γ-globin bands. The
various quality control measures applied to the western blot results were: the density of the bands
in per category must fall within the limits of the average density of that category, each sample
was run in quadruplet, at least three out of the four readings obtained for each sample must be
within 20% of the mean density for all four readings. That is between 80% and 120% of the
quantity mean, otherwise that reading was discarded and not used for further analysis.

2.2.6 Statistical Analysis
The Student’s one-sample, one-tailed t-test was used for statistical analyses. P values <
0.05 for qPCR and P values < 0.025 for qRT-PCR and western blot were considered significant.
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Chapter 3: Results
Regulation of Known γ-globin Gene Repressors by KLF1 in the Mouse and
Human Model Systems

3.1 Introduction
KLF1 is a transcription factor expressed in erythroid cells and is a master regulator of the
hemoglobin switch from fetal (HbF) to adult hemoglobin (HbA) in humans. and embryonic to
adult hemoglobin in mice (Feng WC et al., 1994; Donze D et al., 1995; Wijgerde M et al., 1996;
Perkins AC et al., 1996; Bieker JJ, 1996; Bieker JJ, 2001). KLF1 directly upregulates both β- and
γ-globin gene expression (Alhashem et al., 2011; Borg J et al., 2010; Zhou D et al., 2012;
Tallack MR et al., 2013). In primary cells there is a direct positive linear correlation between
KLF1 and β-globin mRNA levels, but the regulatory role of KLF1 in γ-globin gene expression
seem to be more complex. It was discovered that a 40-70% knockdown of KLF1 in differentiated
primary human cells showed a two-fold increase in γ-globin when compared to the scramble
control samples (Vinjamur D et al., 2016). The primary cells with a robust knockdown of
KLF1, i.e., greater than 80%, showed an almost identical γ-globin level as that of the scramble
cells (Vinjamur D et al., 2016). This suggests that KLF1 is responsible for repressing γ-globin
gene expression, but introduced the concept of a threshold amount of KLF1 which is required by
erythroid cells to increase γ-globin mRNA over normal levels. That is why in this research, we
utilized the threshold amount of KLF1- in the mouse as the genotype KLF1+/-; and in the human
as the K1V1 lentivirus. The K1V1 lentivirus gives a KLF1 knockdown range between 40% and
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70%, also referred to as modest knockdown. The other lentivirus, K1V2, gives a KLF1
knockdown efficiency of >75% and is referred to as robust knockdown.
This phenomenon becomes important when trying to identify potential therapeutic targets to
cure β-hemoglobinopathies like sickle cell disease and β-thalassemia’s. It should also be stated
that KLF1, unlike other γ-globin gene repressors, only affects erythropoietic processes, giving it
another advantage over other target genes.
An evolutionary conservation study was performed on three master regulators of
erythropoiesis, GATA1, NFE2 and KLF1 to examine their occupancy sites in proerythroblasts
over 75 million years, i.e., between mouse and human (Ulirsch JC et al., 2014). GATA1 and
NFE2 showed approximately 25% of master regulatory sites were conserved. Interestingly,
>60% of KLF1 occupancy peaks were conserved between species along the proerythroblast
differentiation lineage (Ulirsch JC et al., 2014; Pishesha N et al., 2014). This is in keeping with
research showing that specific master transcriptional regulators are conserved in both of these
species (Orkin SH et al., 2008; Cantor AB et al., 2002; Wu W et al., 2011). It is of interest to
observe the KLF1 binding in the γ-globin gene repressors to determine if there is any
evolutionary conservation of function and binding of KLF1 between mouse and human. KLF1 is
a transcription factor that binds a specific 9 base pair consensus sequence 5’- CCM-CRC-CCN 3’, (where R represents A or G and M represents A or C) (Feng, Southwood, Bieker 1994; Miller
and Bieker 1993; Tallack et al. 2010). These sites are found throughout the mouse and human
genome (Tallack et al., 2010). If a protein directly regulates expression of another gene binding
may occur within the promoter region of that gene. This has been shown to be the case for
binding of KLF1 to the mouse βh1-globin promoter and human γ- and β-globin promoters
(Alhashem Y et al., 2011). Thus, the first two aims of this research project further assess how
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KLF1 indirectly downregulates γ-globin gene expression by studying transcription levels. Then,
KLF1 binding by identifying the specific 9 base pair sequence in the promoter regions of these
five known γ-globin gene repressors. This was done in both the mouse and human systems using
the aforementioned threshold amount of KLF1.
HUDEP-2 cells are immortalized cells that were established by delivering a Tet-inducible
HPV16-E6/E7 lentiviral transgene in CD34+ cells isolated from human umbilical cord blood
(Nakamura Y et al., 2013). These cells are much easier to expand and differentiate than primary
human cells. The erythroblasts isolated from HUDEP-2 cells are physiologically more similar to
adult erythroblasts than the erythroblasts isolated from primary human cells which tend to be
more fetal-like. It was of interest to see if the phenomenon of KLF1 threshold amount could be
observed in the HUDEP-2 cells as was previously seen in the primary human cells (Vinjamur D
et al., 2016), i.e., they could be characterized similarly with respect to γ-globin and β-globin
mRNA levels when KLF1 knockdown is induced in the cells. After this characterization it was of
importance for us to look at the protein levels of the globins to ensure that protein plot is similar
to the mRNA plot of percent γ-or β-globin vs. residual KLF1. Thus we focused on
characterization of the γ-globin and β-globin mRNA and protein levels in HUDEP-2 cells with
various knockdowns of KLF1.

3.2 LSD1 and LRF are Regulated by KLF1 in Mice
As stated before, KLF1 positively regulates β-globin gene expression whereas it both directly
positively and indirectly negatively regulates γ-globin gene expression. Five known γ-globin
gene repressors namely, Mi2-β, MBD2, c-MYB, LRF and LSD1 were examined, to determine
whether or not KLF1 regulates them. To do this we mated KLF1 +/+ and KLF1 +/- mice to
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obtain KLF1 +/+ and KLF1 +/- fetuses at Embryonic day 12.5 (E12.5) and E14.5. In doing so,
we were able to make use of the modest knockdown of KLF1 that increased γ-globin in CD34+
cells, i.e. the KLF1 +/- mice are comparable genotypically to cells with the modest KLF1
knockdown. E12.5 mouse fetal livers were used as a majority of cells present in the fetal liver are
erythroid and by E14.5 more of the cells are hepatocytes (Crawford LW et al., 2010; Dzierzak, E
et al., 2013).

3.2.1 KLF1 Upregulates LRF and LSD1 Genes in Mouse E12.5 Fetal Livers
After analyzing the qRT-PCR data, the average mRNA expression level normalized to
Cyclophilin A was compared between 8 KLF1 +/+ and 8 KLF1 +/- E12.5 samples, where the
KLF1 +/+ values were set to 100% (Figure 3.1). It was observed that in KLF1 +/-, the mRNA
amount of LRF was 62±6% and the LSD1 mRNA was 31±7%, compared to 100% in KLF1 +/+
(Figure 3.1 B & C), which was significant. A single sample, one-paired, one-tailed t-test was
performed to test whether KLF1 +/- values were statistically significant from KLF1 +/+ values.
However, there was no statistically significant difference between the expression levels of
MBD2, Mi2-β and c-MYB mRNA in KLF1 +/+ and KLF1 +/- fetal livers (Figure 3.1 A, D & E).
Based on our data it can be concluded that KLF1 positively regulates the LSD1 and LRF genes
in the mouse fetal liver. KLF1 does not appear to have any measurable effect on the MBD2,
Mi2-β or c-MYB genes in E12.5 mouse fetal livers.

3.2.2 KLF1 Binds the Promoters of LRF and LSD1 Genes in Mouse E12.5 Fetal Livers
To determine whether the LRF and LSD1 genes are directly regulated by KLF1, KLF1-ChIP
was performed using mouse fetal liver cells. First, all 9 base pair and complementary consensus
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sites were identified in the promoter regions of the genes – LRF and LSD1 (Table 3.1). After
performing the ChIP assay on the chromatin, the average size of the fragments ranges from 100
bp to 300 bp, seen in the 2nd to 4th lanes of the gel (Figure 3.2).
Out of all consensus binding sites present in the promoter regions of LRF and LSD1 from
Table 3.1 we selected three sites for LRF (Figure 3.3 A) and two sites for LSD1 (Figure 3.3 B)
genes which are highlighted in red.

Figure 3.1: KLF1 Upregulates LRF and LSD1 Genes in Mouse E12.5 Fetal Livers
A qRT-PCR was performed on γ-globin gene repressors A) c-MYB, B) LRF, C) LSD1, D) MBD2 and
E) Mi2-β. Paired mouse fetal livers were dissected from E12.5 KLF1 +/+ and KLF1 +/- fetuses, for
RNA extraction. The amount of KLF1 mRNA was measured using qRT-PCR methods and expressed
using the EdCT method to allow for direct comparison of mRNAs from paired fetuses. Cyclophilin A
was used as a normalization control. N=8 per genotype; Error bars represent SD; *, P < 0.05 (PairedStudent’s one-tailed test)

There was a 1.8 fold increase in relative enrichment of the -511 to -492 promoter region of
mouse LRF gene when compared to mouse IgG, which is statistically significant. A 1.6 fold
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increase in relative enrichment of the -214 to -206 promoter region of mouse LSD1 gene when
compared to mouse IgG that was statistically significant (Figure 3.4 A). The mouse β-actin
promoter was used as a negative control and as expected showed no statistically significant
binding of KLF1. The β-major promoter was used as the positive control and a statistically
significant 1.8 fold increase in relative enrichment was obtained when compared to IgG. Based
on our data it can be concluded that KLF1 binds to the mouse LSD1 and LRF promoters at
positions -214 to -206 and -511 to -492, respectively.

Table 3.1: The Mouse Consensus Sequences Located in the Promoter Regions of LSD1 and
LRF Genes
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Figure 3.2: Average Chromatin Fragment Size after Sonication of Mouse Fetal Livers
A 1.5% agarose gel was run with 100 base pair ladder. 1st lane is chromatin before sonication. 2nd- 4th
lanes are chromatin fragments of E12.5 mouse fetal liver cells, 5th – 7th lanes are chromatin fragments
of E14.5 mouse fetal liver cells.
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Figure 3.3: Promoter Regions of Mouse LRF and LSD1 Genes
Promoter regions were acquired from Ensembl. The consensus sites are highlighted in yellow and
primers in red or blue. A) LRF Promoter Region with LRF1 and LRF2 consensus sites and B) LSD1
Promoter Region with LSD1-1 and LSD1-2 consensus sites highlighted in yellow.

3.2.3 No Evidence that KLF1 Binds LRF and LSD1 Promoters in Mouse E14.5 Fetal
Livers
A mouse KLF1-ChIP assay was performed on E14.5 mouse fetal livers because previous data
analyzed from two KLF1 ChIP-seqs was performed on E14.5 in 2010 and 2011 (Tallack MR et
al., 2010; Pilon AM et al., 2011). This data showed that KLF1 does not bind mouse LRF or
LSD1 in their promoters (Figure 3.4 B).
Therefore, to negate the effect of biological differences between our E12.5 ChIP assay
results and the E14.5 ChIP-seq results, a ChIP assay was also performed on E14.5 mouse fetal
liver. The same three consensus sites in the promoter region of the LRF gene were examined:
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After performing the ChIP assay on the chromatin, the average size of the fragments range from
100 bp to 400 bp, seen in the 5th to 7th lanes of the gel (Figure 3.2). There was no significant
increase or decrease in relative fold enrichment of the mouse LSD1 and LRF genes when
compared to mouse IgG (Figure 3.4 C). The negative control, mouse β-actin promoter showed no
significant increase or decrease in relative fold enrichment when compared to the control IgG
enrichment. The positive control, β-major promoter showed a statistically significant 6-fold
enrichment compared to IgG. Based on our data there is no evidence that KLF1 binds the mouse
LSD1 and LRF genes at positions -214 to -206 and -511 to -492 respectively in E14.5 mouse
fetal livers. This is in agreement with the aforementioned research on E14.5 mouse fetal livers
(Tallack MR et al., 2010; Pilon AM et al., 2011).
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Figure 3.4: KLF1 Binding in E12.5 and E14.5 Mouse Fetal Livers
ChIP assays were performed on A) E12.5 and C) E14.5 fetal livers of normal, non-transgenic mice.
Polyclonal antibody specific for KLF1 and non-specific IgG control antibody were used. The Y-axis
represents the relative fold enrichment. The mean IgG enrichment was set as 1.0 and the enrichment of
KLF1 was scaled appropriately. The X- axis shows the location of the primers used for qPCR (Pr:
promoter). The error bars indicate standard error mean (SEM); N = 3; *, P < 0.05 (Paired-Student’s
one-tailed test). B) Data analysis of mouse E14.5 fetal livers KLF1 ChIP-seq data showing the peaks
of KLF1 at the β-globin gene promoters and the LSD1 and LRF promoter regions.
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3.3 Characterization of γ-globin and β-globin mRNA Amounts with Corresponding KLF1
mRNA Amounts in HUDEP-2 Cells
Currently, there is no data on the characterization of the γ-globin and β-globin mRNA and
protein levels in the HUDEP-2 cells with respect to KLF1 knockdown. Similar to the
experiments performed using erythroblasts derived from umbilical cord blood CD34+ cells, we
performed lentiviral infection of the various KLF1 knockdowns in HUDEP-2 cells. As stated
before all experiments using HUDEP-2 cells utilize the threshold amount of KLF1. That is the
KLF1 modest knockdown, designated as K1V1 giving a range between 40% and 70%. The
KLF1 robust knockdown, K1V2, gives a KLF1 knockdown efficiency of >75%. Prior to
examining the role of KLF1 in regulating the five γ-globin repressor genes, the KLF1 mRNA
levels were tested to show that these knockdowns worked.

3.3.1 Raw KLF1, γ-globin and β-globin mRNA Levels Sorted by Knockdown Category in
HUDEP-2 Cells
The raw values of KLF1, γ-globin and β-globin mRNA levels normalized to Cyclophilin A
sorted by category are depicted (Figure 3.5). To verify that our knockdowns of KLF1 worked we
looked at expression levels of KLF1 in the three various categories (Figure 3.5 A). We then were
interested in analyzing the γ-globin (Figure 3.5 B) and β-globin (Figure 3.5 C) expression levels
with respect to KLF1 knockdowns. The γ-globin expression levels show a significant increase in
the K1V1 group as compared to scramble and K1V2 levels. No significant increase or decrease
in γ-globin expression levels is noted in the K1V2 group when comparted to the scramble
control. When comparing the scramble control values of γ-globin expression to the control
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values of β-globin expression we observe that the total γ-globin i.e. γ/ (γ +β) = 20/220 is 11% in
control cells with the scramble lentivirus. A significant increase in γ-globin of the HUDEP-2

samples is seen between scramble control and K1V1 (modest knockdown). A significant
Figure 3.5: Raw Values of KLF1, β-globin and γ-globin mRNA Expression Levels by
Category in HUDEP-2 Cells.
Raw values of A) KLF1, B) γ-globin, C) β-globin, D) Total globin and E) γ-globin over total globin
mRNA sorted by category. The error bars indicate SD; N = 5 per category; P-values as indicated, ns =
not significant (Paired-Student’s one-tailed test, P < 0.025)

increase is also seen in γ-globin of the HUDEP-2 samples when comparing K1V1 and K1V2
(robust knockdown). We see that there is no significant difference in total globin when
comparing the modest knockdown category to the scramble control (Figure 3.5 D). But we do
see a significant decrease in total globin when comparing the robust knockdown to both modest
knockdown and scramble control groups. The γ-globin over total globin is significantly increased
in both K1V1 and K1V2 groups when compared to the control group (Figure 3.5 E). Overall the
results show that the K1V1 and K1V2 shRNAs give KLF1 knockdowns as previously shown. A
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significant decrease in β-globin levels is observed with the K1V2 knockdown samples when
compared to both the scramble control and K1V1 knockdown samples. It should be noted that
protein amounts of KLF1 in the categories was calculated in human CD34+ cells isolated from
fetal umbilical cord blood and showed corresponding protein amounts to their mRNA amounts
(Vinjamur DS et al., 2016). The HUDEP-2 cell line is derived from umbilical cord blood and so
we would expect the protein levels of KLF1 in each category to correspond to mRNA levels
here.

3.3.2 γ-globin and β-globin Protein Levels Correlate with mRNA Levels in HUDEP-2
Cells
It was of interest to determine if the γ- and β-globin protein amounts correspond to their
mRNA amounts with respect to KLF1 knockdown. Relative densities normalized to β-actin
bands of the 16 kDa β-globin (Figure 3.6 A) and 18 kDa γ-globin (Figure 3.6 B) bands were
calculated. There is a significant reduction in expression of β-globin protein by ~4.8-fold upon
knockdown of KLF1 with K1V2 shRNA when compared to both K1V1 and scramble categories
(Figure 3.6 C). This is greater than the ~2-fold reduction of β-globin mRNA at the K1V2
category when compared to scramble control and K1V1 (Figure 3.5 C).
There is a significant increase in expression of γ-globin protein by ~2.0-fold upon
knockdown of KLF1 with K1V1 shRNA when compared to both K1V2 and scramble categories
(Figure 3.6 D). This is similar to the ~2-fold increase of γ -globin mRNA at the K1V1 category
when compared to control and K1V2 (Figure 3.5 B). This shows that only the modest
knockdown of KLF1 results in significant increase in γ-globin protein.

75

Figure 3.6: γ-globin and β-globin Protein Levels Correlate with mRNA Levels in
HUDEP-2 Cells
A) β-globin and B) γ-globin protein levels with respect to corresponding KLF1 protein
levels. 1st – 2nd lanes are scramble controls, 3rd – 4th lanes are the K1V1 (KLF1 modest KD) samples
and 5th – 6th lanes are the K1V2 (KLF1 robust KD) samples. Relative C) β-globin and D) γ-globin
protein levels sorted by category. The error bars indicate SD; N = 3 or 4 per category; P-values as
indicated, ns = not significant (Paired-Student’s one-tailed test, P < 0.025)

3.3.3 β-globin and KLF1 mRNA Amounts Show a Linear Correlation in HUDEP-2 Cells
After analyzing the qRT-PCR data, the average mRNA expression level normalized to
Cyclophilin A was compared between 5 scramble (control), 5 K1V1 and 5 K1V2 samples, where
the scramble values were set to 100% (Figure 3.7). To test whether our KLF1-shRNAs worked

76

the average KLF1 mRNA levels were measured in each group and compared to the scramble set
to 100 (Figure 3.7 A). The K1V1 category had relative KLF1 mRNA amounts of a mean of 57%
and the K1V2 had a mean 25% compared to scramble set to 100%. Similar to the CD34+
erythroid cells, there is an increase in γ-globin mRNA expression in the K1V1 category of 163%
as compared to the scramble control samples set at 100%, which is statistically significant. The
K1V2 knockdown category shows a mean of 98% γ-globin mRNA, which is not statistically
significant to the scramble control samples. Next, the β-globin mRNA levels were observed in
each category (Figure 3.7 B). There was no statistically significant decrease in relative
expression of β-globin mRNA when K1V1 and scramble control categories were compared,
however there was a significant difference between K1V2 and scramble control (Figure 3.7 C).
This was been seen previously in primary cells (Vinjamur DS et al., 2016). When all the samples
were plotted with the scramble control set to 100%, the results are interesting (Figure 3.8). A
linear regression was performed to examine the correlation between β-globin (Figure 3.8 A).
There is a direct positive correlation with an R2 value = 0.92 that is statistically significant for βglobin and KLF1 mRNA levels. Therefore, it can be said that regulation of β-globin by KLF1 is
linear.
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3.3.4 γ-globin and KLF1 mRNA Amounts Have a Non-Linear Relationship in HUDEP-2
Cells
A linear regression was performed to examine the correlation between γ-globin (Figure 3.8
C) mRNA levels to the residual percent of KLF1 present. There is no direct positive correlation
between γ-globin and KLF1 mRNA levels. A smooth curve was fit to the graph, to determine if
the threshold amount of KLF1 with respect to γ-globin mRNA levels is seen (Figure 3.8 D). In
fact, the results obtained in the HUDEP-2 cells were much better than expected, in that, the γglobin mRNA to KLF1 mRNA curve is very tight. Therefore, it can be said that KLF1 regulation
of γ-globin is non-linear. A threshold amount of KLF1 is required for induced g-globin mRNA.
It is clear in figure 3.8 D that when residual KLF1 is between 50% to 60% we observe γ-globin
mRNA increases nearly 2-fold. With knockdown less or greater than this, baseline mRNA levels
of γ-globin amounts are observed.

Figure 3.7: γ-globin and β-globin mRNA Levels in HUDEP-2 Cells Mimic Those Seen in
CD34+ Cells Isolated from Umbilical Cord Blood
The amount of A) KLF1 B) γ-globin and C) β-globin mRNA was measured by qRT-PCR and
normalized to Cyclophilin A. mRNA in K1V1 and K1V2 categories as compared to scramble controls
set to 100. The error bars indicate SD; N = 5 per category; P-values as indicated, ns = not significant
(Paired-Student’s one-tailed test).
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Figure 3.8: Regulation of β-globin and γ-globin Expression by KLF1 in HUDEP-2 Cells
Follows Both a Linear and Non-Linear Pattern
The amount of KLF1 mRNA and β-globin or γ-globin mRNA was measured by qRT-PCR and
normalized to Cyclophilin A mRNA. The fold change in KLF1 expression and γ-globin expression in
each sample was calculated by setting the value for each gene in scramble controls to 100. A) A linear
correlation that is statistically significant is observed between amount if KLF1 mRNA and
corresponding amount of β-globin mRNA by linear regression analysis. C) No correlation was
observed between the amount of KLF1 mRNA present in cells and the corresponding amount of γglobin expression by linear regression analysis. B & D) when the data was analyzed by allowing the
statistical program JMP to fit a non-linear model to the available data in an unbiased manner, the
smooth curves shown in the figures were obtained. The non-linear model supports our interpretation
of the data with regard to sensitivity of the regulation of γ-globin gene expression to the amount of
KLF1 available in cells. n = 5 per category. Each dot on the scatter-plot represents a biological
sample, i.e., cells obtained from one HUDEP-2 cell sample.

3.4 KLF1 Indirectly Downregulates γ-globin Gene Expression
Similar to the qRT-PCR experiments performed in mice, the same five known γ-globin gene
repressors were examined in HUDEP-2 cells. That is the Mi2-β, MBD2, c-MYB, LRF and LSD1
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genes, and whether they are regulated by KLF1. This was performed by lentiviral infection of the
various KLF1 knockdowns in HUDEP-2 cells.

3.4.1 KLF1 Regulates Human LRF, LSD1 and c-MYB Genes in HUDEP-2 cells
After analyzing the qRT-PCR data, the average mRNA expression level normalized to
Cyclophilin A was compared between 5 scramble (control), 5 K1V1 and 5 K1V2 samples, where
the scramble values were set to 100 (Figure 3.9). LRF was the only gene to be significantly
downregulated with modest knockdown of KLF1, i.e., the LRF mRNA amount with the modest
knockdown was 89± 4 (Figure 3.9 A). The human c-MYB, LRF and LSD1 mRNAs showed a
statistically significant difference between the robust knockdown and scramble (Figure 3.9 A –
C). The gene expression levels with robust knockdown were 90±7, 70±6 and 89±10 for c-MYB,
LRF and LSD1 respectively, when compared to the scramble. MBD2 and Mi2-β showed no
statistically significant change in gene expression levels at any knockdown level (Figure 3.9 D &
E). A single sample, one-paired, one-tailed t-test was performed to show the values that are
statistically significant. Based on our data from the HUDEP-2 cells it can be concluded that
human KLF1 positively regulates mouse LRF with the modest knockdown and the human cMYB, LRF, LSD1 and MBD2 genes with the robust knockdown and does not regulate Mi2-β at
all. Interestingly, these same four genes showed statistically significant change in relative gene
expression when comparing the modest and robust knockdowns. Based on our data it can be
concluded that human KLF1 positively regulates human LRF with modest knockdown,
positively regulates c-MYB, LRF and LSD1 with robust knockdown and negatively regulates
MBD2 with a robust knockdown in HUDEP-2 cells. KLF1 does not have any detectable effect
on the Mi2-β gene expression in HUDEP-2 cells.
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Figure 3.9: KLF1 Regulates Human LRF, LSD1 and c-MYB Genes in HUDEP-2 Cells
A qRT-PCR was performed on γ-globin gene repressors A) c-MYB, B) LRF, C) LSD1, D) MBD2
and E) Mi2-β. 5 samples each of HUDEP-2 cells infected with scramble, K1V1 or K1V2 were
collected, for RNA extraction. The amount of KLF1 mRNA was measured using qRT-PCR methods
and expressed using the EdCT method to allow for direct comparison of mRNAs to scramble (set to
100). Cyclophilin A was used as a normalization control. N=5 per category; Error bars represent SD;
P-values as indicated, ns = not significant (Paired-Student’s one-tailed test, P < 0.025).

3.4.2 KLF1 Binds the Promoter Region of the Human LRF Gene in HUDEP-2 Cells
Next we wanted to determine whether the c-MYB, LRF, LSD1 and MBD2 genes are bound
by KLF1 by performing a human KLF1-ChIP. Before beginning the human KLF1-ChIP assays
the 9 base pair and complementary consensus sites were taken from Table 3.2, for these four
genes. Out of all consensuses binding sites present in the promoter regions of c-MYB, LRF,
LSD1and MBD2 we selected 6 sites for the LRF (Figure 3.10 A), three for the LSD1 (Figure
3.10 B), three for the c-MYB (Figure 3.10 C) and four for the MBD2 (Figure 3.10 D) genes
which are highlighted in red. After performing the ChIP assay the chromatin was run on a qPCR
and the data was analyzed, the average size of the fragments are on average between 400 bp to
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800 bp, seen in the 1st to 3rd lanes of the gel (Figure 3.11). There was a 3.5 fold increase of the 478 to -470, a 4.2 fold increase of the -409 to -351 and a 4.5 fold increase of the -25 to -9 relative
fold enrichment in the promoter region of the human LRF gene when compared to human IgG
(Figure 3.12). The human β-globin and γ-globin gene promoters, used as controls, showed an 8.1
and 6.4 increase in fold enrichment for KLF1, respectively. The negative control, Necdin,
showed no statistically significant change in relative fold change with respect to IgG. To
summarize, from our data it appears that KLF1upregulates c-MYB, LRF and LSD1 while
simultaneously downregulating MBD2. KLF1 directly binds the promoter sites of the LRF gene.
There is no evidence that KLF1 binds the promoter regions of the other three genes.
Interestingly, it is observed that the γ-globin promoter is bound by KLF1 more in HUDEP-2 cells
than in erythroblasts derived from umbilical cord blood CD34+ cells (Alhashem Y et al., 2011).
KLF1 binding γ-globin: β-globin is ~4:3 in HUDEP-2 samples and ~1:1 in primary erythroid
cells derived from CD34+ umbilical cord blood cells.

82

Table 3.2: The Human Consensus Sequences Located in the Promoter Regions of LSD1,
LRF, MBD2 and c-MYB Genes.
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Figure 3.10: Promoter Regions of Human LRF, LSD1, c-MYB and MBD2 Genes
Promoter regions were acquired from Ensembl. The consensus sites are highlighted in yellow and
primers in red or blue. A) LRF promoter region with LRF1, LRF2, LRF3 and LRF4 consensus sites,
B) LSD1 promoter region with LSD1-1, LSD1-2 and LSD1-3 consensus sites, C) c-MYB promoter
region with c-MYB1, c-MYB2 and c-MYB3 consensus sites and D) MBD2 promoter region with
MBD2-1, MBD2-2, MBD2-3 and MBD2-4 consensus sites.
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Figure 3.11: Average Chromatin Fragment Size after Sonication of HUDEP-2 Cells
A 1.5% agarose gel was run with 100 base pair ladder. 1st – 3rd lanes are chromatin fragments of
HUDEP-2 cells.
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Figure 3.12: KLF1 Binds the Promoter Regions of the Human LRF Gene in HUDEP-2
Cells
ChIP assays were performed on, non-transgenic mice. Polyclonal antibody specific for human KLF1
and non-specific IgG control antibody were used. Sequences highlighted in red and blue are the
primers. A) LRF Promoter Region with LRF1, LRF2 and LRF3 consensus sites highlighted in yellow
and B) LSD1 Promoter Region with LSD1-1 and LSD1-2 consensus sites highlighted in yellow. C) cMYB promoter region with c-MYB-1 and c-MYB-2 consensus sites highlighted in yellow. D) MBD2
Promoter region with MBD2-1 and MBD2-2 consensus sites highlighted in yellow. The Y-axis
represents the relative fold enrichment. The mean IgG enrichment was set as 1.0 and the enrichment
of KLF1 was scaled appropriately. The X- axis shows the location of the primers used for qPCR (Pr:
promoter). The error bars indicate standard error mean (SEM); N = 3; *, P < 0.05 (Paired-Student’s
one-tailed test)
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Chapter 4: Discussion and Future Directions

4.1 Discussion
A main focus of this research was to understand the intricate mechanisms by which KLF1
regulates γ-globin in both the mouse and human systems. Based on the data in this thesis,
mouse KLF1 binding to γ-globin repressor genes showed major differences between E12.5
and E14.5 mouse fetal livers. In E14.5 fetal livers, KLF1 binding is in agreement with ChIPseq data from 2011, which shows no evidence that KLF1, binds to the promoter regions of
the LSD1 or LRF genes (Tallack et al., 2010; Pilon AM et al., 2011). On the other hand,
KLF1 in E12.5 mouse fetal livers directly binds the LSD1 and LRF promoter regions, which
goes along with a ChIP-seq performed in the murine cell line, K1-ER cells (Norton LJ et al.,
2017) which identified the LRF promoter region as having one of the most highly enriched
KLF1 peaks (Funnell AP et al., 2012; Hodge D et al., 2006). Another paper showed no
binding to either of these genes in the K1-ER cell line (Tallack MR et al., 2010). The K1-ER
cell lines are used to study the role of KLF1 in erythropoiesis. They were created from
KLF1-/- mouse fetal liver progenitor cells that carry one copy of the human β-globin locus
(Coghill E et al., 2001). Also E14.5 KLF1 -/- fetal livers showed a significant reduction in
expression of LRF when compared to controls (Norton LJ et al., 2017).
There are multiple possible reasons why we see differences in KLF1 binding at different
developmental time points in the mouse LRF gene. First, Norton et al. put forward the theory
that KLF1 and GATA-1 both act to upregulate LRF since GATA-1 activates expression of
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both LRF and KLF1 (Crossley M et al., 1994; Martin DI et al., 1990; Norton LJ et al., 2017).
Second, mouse KLF1 plays a direct role in repressing βh1-globin in earlier embryonic stage
E12.5 and gradually moves to a more indirect role of repressing γ-globin by E14.5. LRF is a
downstream target of GATA-1 (Maeda T et al., 2009), a transcription factor required for
terminal erythroid maturation as mentioned before. What is proposed is LRF is regulated by
KLF1 at E12.5 when terminal erythroid maturation is not in full swing, then at E14.5 GATA1 binds and activates LRF for this purpose of terminal maturation of erythroblasts.
LRF-/- mouse embryos at E12.5 have no morphological abnormalities, by E14.5 gross
morphological abnormalities can be seen (Maeda T et al., 2009). LRF-/- fetuses die in utero
at E15.5 to E16.5 due to lack of differentiation from erythroblast stage to mature
erythrocytes, so it seems logical that by E14.5 GATA-1 would be responsible for all binding
to LRF in E14.5 mice.
KLF1 also binds to the LSD1 promoter at E12.5 but not E14.5. LSD1 removes H3K4me2
an activation methylation mark (Nicholson TB et al., 2009). Therefore we propose that in
E12.5 mouse fetal livers, LSD1 is activated by KLF1, to repress the mouse embryonic-globin
genes. It is possible that this histone modification is then kept as an epigenetic marker during
the M phase of the cell cycle. The next generation of cells could inherit this epigenetic mark
and so by E14.5 the mouse embryonic-globin gene is still being repressed. Therefore, the
need for KLF1 to repress the embryonic-globin genes via activation of LSD1 is no longer
required by E14.5 fetuses.
The recently developed HUDEP-2 cell line has allowed researchers to study regulation of
γ- and β-globin genes in a more regulated environment, i.e. in a human erythroid cell line.
Unlike the other human erythroid cell lines, K562 and HEL, the HUDEP-2 cell line is
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representative of an adult erythroid system and these cells are not chromosomally aberrant
(Nakamura Y et al., 2013). The erythroid HUDEP-2 cells have 97% β-globin and < 2% γglobin content which is considered to be an ‘adult-like’ system. This is in comparison to
primary human erythroid cells isolated from umbilical cord blood that have higher fetal-like
globin levels, i.e. ~50% γ-globin mRNA (Alhashem YN, 2012). From the raw values of γand β-globin in our transfected scramble control HUDEP-2 cells, it was observed that γ / (γ +
β) globin is equivalent to 11%, but our non-transfected mock control γ/ (γ+β) globin is
negligible. Current research shows that HUDEP-2 lentiviral treated control samples have
negligible amounts of γ-globin with differentiation (Masuda T et al., 2016) and also has
approximately 3% to 4% amount of γ-globin (Traxler E et al., 2016). To date, our data shows
the highest percent of γ-globin induced in the HUDEP-2 control samples. A logical
explanation for the relatively high amount of γ-globin observed in scramble control is the
three days of differentiation versus 7 days in the Masuda and Traxler papers. Many cite the
fact that infection of control CD34+ cells with a lentivirus leads to increased HbF (Masuda T
et al., 2016; Vinjamur DS et al., 2016).
When the scramble value is set to 100 and the K1V1 and K1V2 values are adjusted
accordingly we observe that γ-globin gene expression is sensitive to KLF1 dosage. The
robust knockdown of KLF1 (<25% residual KLF1) in samples showed no significant
increase or decrease in -globin mRNA compared to the control. This is the same
phenomenon observed by our lab previously, termed the threshold amount (Vinjamur DS et
al., 2016). That is, the cells have inadequate amounts of KLF1 to increase γ-globin with
robust KLF1 knockdown. Samples with residual KLF1 between 40% and 50% (K1V1),
showed 2-fold higher γ-globin expression than in control samples. This confirms the same
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observations made by our lab in the human primary erythroid cells isolated from umbilical
cord blood (Vinjamur DS et al., 2016). The relative density or intensity of the 16 kDa βglobin and 18 kDa γ-globin protein bands further confirm that what is occurring at the
mRNA level upon various KLF1 knockdowns is also seen at the protein level. It should be
noted that other research shows that there is a 6- to 10-fold increase of γ-globin expression in
adult erythroid cells where KLF1 is depleted (Borg J et al., 2010; Zhou D et al., 2010).
Reasoning for this higher induction of γ-globin than we have observed could be due to the
fact that these samples were differentiated for 7-10 days when γ-globin expression levels are
negligible. Therefore, any increase in γ-globin expression would be multi-fold higher.
Previous research has shown that γ-globin expression decreases when ≤ 10% residual KLF1
is present in primary erythroid cells and upon observing KLF1 -/- βYAC mice (Vinjamur DS
Dissertation, 2014; Alhashem YN et al., 2011). In agreement with this research, we also
noted a slight decrease in γ-globin gene expression with robust knockdowns of KLF1when
compared to scramble control γ-globin expression levels.
Elevated γ-globin expression observed in HUDEP-2 cells with between 40 - 50% residual
KLF1 can be explained with data from this research: First, the dysregulation of γ-globin gene
repressor LRF by being directly bound by KLF1 in the promoter region. Second, indirect
upregulation of Mi2β and LSD1 by KLF1, which are known γ-globin repressor genes.
The threshold amount of KLF1 defined as having at least 40% KLF1 required to see
induction of increased γ-globin expression is seen in the HUDEP-2 cells. Reasoning for this
could be: Reduced competition of the γ-globin promoter for the LCR due to reduced KLF1
binding to its promoter. The probable hypothesis as to why there is a normal amount of γglobin expression and a major decrease in β-globin expression upon depletion of residual
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KLF1 to ≤ 25% may be: A result of multiple processes that require KLF1such as recruitment
of β- and γ-globin genes to transcription factories as well as active chromatin hub formation
at the β-globin locus and interaction between the LCR and the globin gene promoters
(Drissen et al. 2004; Schoenfelder et al. 2010).
The protein levels of β -globin were respectively ~4.8 fold lower in the K1V2 category as
compared to the scramble and K1V1 categories. This is in agreement with mRNA obtained
in human primary cells where a significant decrease in β-globin mRNA is noted when
compared to the other categories, though that showed a 2-fold decrease in expression. γglobin protein levels were respectively ~2.0-fold higher in the K1V1 category as compared to
the scramble and K1V2 categories. This is also in agreement with mRNA obtained in human
primary cells where a similar increase in γ-globin mRNA is noted when compared to the
other categories. This verifies that there is a threshold amount of ~50% KLF1 required to
increase γ-globin protein expression to a significant extent and that the robust knockdown
shows baseline levels of γ-globin protein. Therefore, it can be stated that knockdown of 50%
KLF1 required to increase γ-globin protein expression would be beneficial in treating SCD or
β-thalassemic patients.
Expression levels of γ-globin mRNA do not vary significantly when comparing different
HUDEP-2 samples with relatively similar amounts of residual KLF1. This is in contrast to γglobin expression levels among different samples of primary erythroid cells isolated from
umbilical cord blood. In the primary cell model, each sample is taken from an individual and
hence varies greatly (Vinjamur DS Dissertation, 2014), i.e. a cell line derived from one
patient (HUDEP-2 cells) vs. primary cells from different patients. Overall we conclude that
the HUDEP-2 cells mimic the CD34+ Cells isolated from umbilical cord blood with respect
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to regulation of γ-globin expression by KLF1. Based on evidence from this study, it is
suggested HUDEP-2 cells can be used as an alternative to erythroid primary cells and cell
lines. This is because they more closely resemble the adult erythroid system than do primary
cells and they are not chromosomally aberrant as are other popular cell lines.
This research shows that human KLF1 directly binds the LRF gene promoter, which is in
agreement with recent literature (Norton LJ et al., 2017). Though fragment sizes were too
large to discern between different consensus binding sites in our data, this research showed
that KLF1 binds multiple binding sites in the LRF promoter (Norton LJ et al., 2017). This
data thus gives more merit to our hypothesis that elevated γ-globin expression observed in
cells with 40% to 50% residual KLF1 is caused by the dysregulation of γ-globin repressors
which are regulated by KLF1. KLF1 downregulates MBD2 and upregulate LSD1 and cMYB, but does not bind them in their promoter regions. This could indicate that KLF1 with
many binding sites found at large distances from any of these known genes in mice, could act
at distant enhancers (Tallack et al., 2010) or might function by chromatin looping as seen
particularly with the β-globin locus (Drissen et al., 2004) or directly binds regions of these
genes other than the promoter. Another possibility is KLF1 indirectly regulates these genes
via another repressor in the case of MBD2 or an activator in the case of LSD1 and c-MYB.
The γ-globin gene repressor c-MYB binds the KLF1 promoter and transactivates its
expression (Bianchi E et al., 2010). Based on this research we also see that KLF1 activates cMYB though it does not bind its promoter. KLF1 and c-MYB could act as activators of each
other to ensure repression of γ-globin just as BCL11A and KLF1 do by both activating
BCL11A.
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Also of note, KLF1 shows more binding to the γ-globin gene promoter region than
previously seen in primary erythroid cells (Vinjamur DS et al., 2016). KLF1 may have an
indirect role in γ-globin gene regulation during adult erythropoiesis which is supported by
evidence from previous research (Borg J et al., 2010; Zhou D et al., 2010; Arnaud et al.,
2010; Tallack MR et al., 2013). The γ- to β –globin ratio in human primary cells derived
from umbilical cord blood is ~ 1:1 (Alhashem YN et al., 2011) whereas in HUDEP-2 cells
based on our findings it is 1:9. When we look at evidence on the ratio of KLF1 binding to γglobin to the β-globin promoter we see that: E11.5 βYAC mouse primitive erythroid cells
show an 5:1 ratio (Alhashem YN et al., 2011); HUDEP-2 cells show a 1:1 (Weinert B et al.,
2017) and in our data, HUDEP-2 cells after 3 days of differentiation show a 7.5:9 ratio. This
suggests that KLF1 directly binds and activates the γ-globin gene in its promoter and with
increased binding for γ-globin over β-globin promoter. Our own evidence suggests KLF1
indirectly represses γ-globin during adult erythropoiesis by activating LSD1 and LRF in
E12.5 mouse fetal livers and activating LRF, LSD1 and c-MYB in HUDEP-2 cells.
Therefore, we conclude that KLF1 appears to have a direct role in activating and an indirect
repressive role on γ-globin gene expression in humans.
The human and mouse LRF genes in HUDEP-2 cells (Norton LJ et al., 2017) and E12.5
mouse fetal livers are bound by KLF1 based on our research. This is accordance with other
research that has shown that >60% of KLF1 occupancy peaks along the proerythroblast
lineage are conserved between species (Ulirsch JC et al., 2014; Pishesha N et al., 2014
Therefore, it can be concluded that KLF1 binding the LRF gene is evolutionarily conserved
between mice and humans.
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Based on current research and this research, the proposed human model on how KLF1
regulates γ-globin gene expression can be explained as such: KLF1 directly binds γ-globin
gene to activate expression (Weinert B et al., 2017; Alhashem YN et al., 2011). This is
because the γ-globin gene precludes expression of the β-globin gene in early transgenic
mouse development due to the major γ-globin promoter element, CACCC, which suppresses
β-globin gene expression in the fetus (Sargent TG et al., 1999; Sargent TG et al, 2001). It
was concluded that a protein(s) such as KLF1 binds to the γ-globin CACCC element to
coordinate stage-specific gene expression (Sargent TG et al., 2001). KLF1 directly binds and
activates LRF (Norton LJ et al., 2017) which in-turn represses γ-globin expression (Masuda
T et al., 2016). KLF1 indirectly activates c-MYB and LSD1 which in turn repress γ-globin
expression (Jiang J et al., 2006; Shi L et al., 2013; Rivers A et al., 2015; Cui S et al., 2015).
c-MYB and LSD1 are shown to have indirect activation arrows. This is because this study
did not find any indication of KLF1 binding of these genes in their promoters (Figure 4.1).
Based on this research, it is more likely that KLF1 will make an excellent therapeutic target
for increasing γ-globin protein levels in sickle cell and β-thalassemic patients.
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Figure 4.1: Proposed Model of the Human γ-globin Gene Suppression Network
4.2 Future Directions
This work further elucidates the dichotomous role of KLF1 in regulating γ-globin
expression in the human and mouse systems. Our results suggest that KLF1 indirectly
represses γ-globin gene expression via upregulating γ-globin repressor genes LRF (Masuda T
et al., 2016), LSD1 (Shi L et al., 2013) and c-MYB (Jiang J et al., 2006) and in other studies
BCL11A (Sankaran VG, 2008). This research also suggests a direct activation of γ-globin
gene expression by KLF1. Both these aspects of γ-globin gene regulation by KLF1 can be
broadened into further studies explained in the following paragraphs.
To expand on the indirect repressive role of KLF1 on γ-globin expression in the human
system, the TR2 and TR4 subunits of the DRED complex, a known γ-globin repressor
(Tanabe O et al., 2002), will be studied. This will be done to observe whether KLF1 regulates
and binds these genes directly and our lab has already designed primer sets for each of these
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genes. The next step in elucidating the extent to which KLF1 indirectly represses γ-globin
expression is to perform an unbiased approach of γ-globin repressor genes differentially
expressed genes in HUDEP-2 samples with modest knockdown of KLF1 when compared to
control samples. A list of genes differentially expressed in the knockdown samples compared
to control samples and knockdown samples compared to each other will be compiled. Each
of these listed genes will be ranked on criteria that include but are not limited to: fold
decrease, function in erythropoiesis/hemoglobin switching, potential role as a transcriptional
regulator, etc. Genes selected will then have the same experiments performed as was done on
LRF, LSD1, c-MYB, MBD2 and Mi2-β genes in this study.
To validate the direct binding and activation of γ-globin expression by KLF1 a luciferase
assay will be performed in HUDEP-2 cells. The luciferase gene will be inserted downstream
of the γ-globin gene promoter which includes the 9 base pair consensus sequence required for
KLF1 binding. Light emitted by the mutated consensus sequence and the normal site will be
compared. If the mutated binding site shows decreased light emitted as compared to the
control sample, then it will be concluded that KLF1 directly binds and activates γ-globin
gene expression. Data analysis of KLF1 ChIP-seq data on the HUDEP-2 cells would also be
of interest to identify direct binding of KLF1 to γ-globin repressor genes (Norton LJ et al.,
2017).
The fragment sizes of HUDEP-2 cell chromatin looking at KLF1 binding in LRF were
too large to discern which of the consensus sequences KLF1 binds. Therefore, another
experiment would identify which of these consensus sequences by KLF1 is most efficacious
in activating human LRF. This will also be done by performing a luciferase assay with each
site being mutated and then compared to the control sample. The LRF promoter region from
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+1 to -500 of the LRF TSS will be cloned upstream of the luciferase gene in an expression
vector, each clone will have one consensus site mutated compared to a control with no
mutations. The DNA vector will be introduced into the HUDEP-2 cells (or other sample).
The HUDEP-2 cell line is a relatively new human adult-like system used in this field. So
it is assumed that the cells at differentiation day 3 resemble those human primary cells at
differentiation day 8 with regard to erythroblast maturity. To verify that this is the case, first,
cytospin slides at HUDEP-2 differentiation day 3are prepared to score the level of erythroid
maturity as previously done in human primary cells (Alhashem YN, 2012). The scoring is
based on the number of cells out of 100 at each erythroblast stage, i.e. basophilic,
polychromatic or orthochromatic erythroid cells. We would expect to see no significant
difference in the number of cells at each stage in the K1V1 and K1V2 samples when
compared to the control. Second, fluorescent-activated cell sorting (FACS) will be performed
to identify the percentage of cells with transferrin (CD71) and glycophorin A (CD235a)
receptors in K1V1 and K1V2 knockdown compared to the scramble control.
The ultimate aim of a study like this is to design an ideal targeted therapy strategy to
increase γ-globin expression and alleviate symptoms associated with sickle cell disease. That
is why, we would like to compare levels of five to 6 of the most efficacious γ-globin
repressor genes in sickle cell disease patients with low HbF and high HbF. ShRNAs will be
created to knockdown each gene individually for testing which gene or combination of two
genes gives the highest induction of HbF.
Finally, our work confirms the role of KLF1 in regulating γ-globin gene expression and
shows that modest knockdown of KLF1 is a viable option for induction of γ-globin gene
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expression. In addition it establishes the conserved binding by KLF1 in both the mouse and
human systems to the γ-globin repressor gene LRF.
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